id	sid	tid	token	lemma	pos
dpc-2053	1	1	dermatology	dermatology	NOUN
dpc-2053	1	2	:	:	PUNCT
dpc-2053	1	3	practical	practical	ADJ
dpc-2053	1	4	and	and	CCONJ
dpc-2053	1	5	conceptual	conceptual	ADJ
dpc-2053	1	6	original	original	ADJ
dpc-2053	1	7	article	article	NOUN
dpc-2053	1	8	|	|	ADV
dpc-2053	1	9	dermatol	dermatol	ADJ
dpc-2053	1	10	pract	pract	NOUN
dpc-2053	1	11	concept	concept	NOUN
dpc-2053	1	12	.	.	PUNCT
dpc-2053	2	1	2022;12(4):e2022148	2022;12(4):e2022148	NUM
dpc-2053	2	2	1	1	NUM
dpc-2053	2	3	omalizumab	omalizumab	NOUN
dpc-2053	2	4	for	for	ADP
dpc-2053	2	5	the	the	DET
dpc-2053	2	6	treatment	treatment	NOUN
dpc-2053	2	7	of	of	ADP
dpc-2053	2	8	chronic	chronic	ADJ
dpc-2053	2	9	spontaneous	spontaneous	ADJ
dpc-2053	2	10	urticaria	urticaria	NOUN
dpc-2053	2	11	:	:	PUNCT
dpc-2053	2	12	association	association	NOUN
dpc-2053	2	13	between	between	ADP
dpc-2053	2	14	body	body	NOUN
dpc-2053	2	15	mass	mass	NOUN
dpc-2053	2	16	index	index	NOUN
dpc-2053	2	17	and	and	CCONJ
dpc-2053	2	18	outcome	outcome	NOUN
dpc-2053	2	19	irene	irene	PROPN
dpc-2053	2	20	russo1,2	russo1,2	PROPN
dpc-2053	2	21	,	,	PUNCT
dpc-2053	2	22	sara	sara	PROPN
dpc-2053	2	23	cazzolla1	cazzolla1	PROPN
dpc-2053	2	24	,	,	PUNCT
dpc-2053	2	25	francesca	francesca	PROPN
dpc-2053	2	26	pampaloni1	pampaloni1	PROPN
dpc-2053	2	27	,	,	PUNCT
dpc-2053	2	28	mauro	mauro	PROPN
dpc-2053	2	29	alaibac1	alaibac1	NOUN
dpc-2053	2	30	1	1	NUM
dpc-2053	2	31	unit	unit	NOUN
dpc-2053	2	32	of	of	ADP
dpc-2053	2	33	dermatology	dermatology	NOUN
dpc-2053	2	34	,	,	PUNCT
dpc-2053	2	35	department	department	NOUN
dpc-2053	2	36	of	of	ADP
dpc-2053	2	37	medicine	medicine	NOUN
dpc-2053	2	38	(	(	PUNCT
dpc-2053	2	39	dimed	dimed	PROPN
dpc-2053	2	40	)	)	PUNCT
dpc-2053	2	41	,	,	PUNCT
dpc-2053	2	42	university	university	NOUN
dpc-2053	2	43	of	of	ADP
dpc-2053	2	44	padova	padova	PROPN
dpc-2053	2	45	,	,	PUNCT
dpc-2053	2	46	padua	padua	PROPN
dpc-2053	2	47	,	,	PUNCT
dpc-2053	2	48	italy	italy	PROPN
dpc-2053	2	49	2	2	NUM
dpc-2053	2	50	soft	soft	ADJ
dpc-2053	2	51	-	-	PUNCT
dpc-2053	2	52	tissue	tissue	NOUN
dpc-2053	2	53	,	,	PUNCT
dpc-2053	2	54	peritoneum	peritoneum	NOUN
dpc-2053	2	55	and	and	CCONJ
dpc-2053	2	56	melanoma	melanoma	ADJ
dpc-2053	2	57	surgical	surgical	ADJ
dpc-2053	2	58	oncology	oncology	NOUN
dpc-2053	2	59	unit	unit	NOUN
dpc-2053	2	60	,	,	PUNCT
dpc-2053	2	61	veneto	veneto	PROPN
dpc-2053	2	62	institute	institute	PROPN
dpc-2053	2	63	of	of	ADP
dpc-2053	2	64	oncology	oncology	NOUN
dpc-2053	2	65	(	(	PUNCT
dpc-2053	2	66	iov)irccs	iov)irccs	PROPN
dpc-2053	2	67	,	,	PUNCT
dpc-2053	2	68	padua	padua	PROPN
dpc-2053	2	69	,	,	PUNCT
dpc-2053	2	70	italy	italy	PROPN
dpc-2053	2	71	key	key	ADJ
dpc-2053	2	72	words	word	NOUN
dpc-2053	2	73	:	:	PUNCT
dpc-2053	2	74	omalizumab	omalizumab	NOUN
dpc-2053	2	75	,	,	PUNCT
dpc-2053	2	76	chronic	chronic	ADJ
dpc-2053	2	77	spontaneous	spontaneous	ADJ
dpc-2053	2	78	urticaria	urticaria	NOUN
dpc-2053	2	79	,	,	PUNCT
dpc-2053	2	80	bmi	bmi	PROPN
dpc-2053	2	81	citation	citation	NOUN
dpc-2053	2	82	:	:	PUNCT
dpc-2053	2	83	russo	russo	PROPN
dpc-2053	2	84	i	i	PRON
dpc-2053	2	85	,	,	PUNCT
dpc-2053	2	86	cazzolla	cazzolla	PROPN
dpc-2053	2	87	s	s	PROPN
dpc-2053	2	88	,	,	PUNCT
dpc-2053	2	89	pampaloni	pampaloni	NOUN
dpc-2053	2	90	f	f	X
dpc-2053	2	91	,	,	PUNCT
dpc-2053	2	92	alaibac	alaibac	PROPN
dpc-2053	2	93	m.	m.	NOUN
dpc-2053	2	94	omalizumab	omalizumab	NOUN
dpc-2053	2	95	for	for	ADP
dpc-2053	2	96	the	the	DET
dpc-2053	2	97	treatment	treatment	NOUN
dpc-2053	2	98	of	of	ADP
dpc-2053	2	99	chronic	chronic	ADJ
dpc-2053	2	100	spontaneous	spontaneous	ADJ
dpc-2053	2	101	urticaria	urticaria	NOUN
dpc-2053	2	102	:	:	PUNCT
dpc-2053	2	103	association	association	NOUN
dpc-2053	2	104	between	between	ADP
dpc-2053	2	105	body	body	NOUN
dpc-2053	2	106	mass	mass	NOUN
dpc-2053	2	107	index	index	NOUN
dpc-2053	2	108	and	and	CCONJ
dpc-2053	2	109	outcome	outcome	NOUN
dpc-2053	2	110	.	.	PUNCT
dpc-2053	3	1	dermatol	dermatol	NOUN
dpc-2053	3	2	pract	pract	PROPN
dpc-2053	3	3	concept	concept	NOUN
dpc-2053	3	4	.	.	PUNCT
dpc-2053	4	1	2022;12(4):e2022148	2022;12(4):e2022148	X
dpc-2053	4	2	.	.	PUNCT
dpc-2053	4	3	doi	doi	PROPN
dpc-2053	4	4	:	:	PUNCT
dpc-2053	4	5	https://doi.org/10.5826/dpc.1204a148	https://doi.org/10.5826/dpc.1204a148	PROPN
dpc-2053	4	6	accepted	accept	VERB
dpc-2053	4	7	:	:	PUNCT
dpc-2053	4	8	january	january	PROPN
dpc-2053	4	9	21	21	NUM
dpc-2053	4	10	,	,	PUNCT
dpc-2053	4	11	2022	2022	NUM
dpc-2053	4	12	;	;	PUNCT
dpc-2053	4	13	published	publish	VERB
dpc-2053	4	14	:	:	PUNCT
dpc-2053	4	15	october	october	PROPN
dpc-2053	4	16	2022	2022	NUM
dpc-2053	5	1	copyright	copyright	NOUN
dpc-2053	5	2	:	:	PUNCT
dpc-2053	5	3	©	©	PROPN
dpc-2053	5	4	2022	2022	NUM
dpc-2053	5	5	russo	russo	NOUN
dpc-2053	5	6	et	et	PROPN
dpc-2053	5	7	al	al	PROPN
dpc-2053	5	8	.	.	PUNCT
dpc-2053	6	1	this	this	PRON
dpc-2053	6	2	is	be	AUX
dpc-2053	6	3	an	an	DET
dpc-2053	6	4	open	open	ADJ
dpc-2053	6	5	-	-	PUNCT
dpc-2053	6	6	access	access	NOUN
dpc-2053	6	7	article	article	NOUN
dpc-2053	6	8	distributed	distribute	VERB
dpc-2053	6	9	under	under	ADP
dpc-2053	6	10	the	the	DET
dpc-2053	6	11	terms	term	NOUN
dpc-2053	6	12	of	of	ADP
dpc-2053	6	13	the	the	DET
dpc-2053	6	14	creative	creative	ADJ
dpc-2053	6	15	commons	common	NOUN
dpc-2053	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2053	6	17	license	license	NOUN
dpc-2053	6	18	(	(	PUNCT
dpc-2053	6	19	by	by	ADP
dpc-2053	6	20	-	-	PUNCT
dpc-2053	6	21	nc-4.0	nc-4.0	NOUN
dpc-2053	6	22	)	)	PUNCT
dpc-2053	6	23	,	,	PUNCT
dpc-2053	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2053	6	25	,	,	PUNCT
dpc-2053	6	26	which	which	PRON
dpc-2053	6	27	permits	permit	VERB
dpc-2053	6	28	unrestricted	unrestricted	ADJ
dpc-2053	6	29	noncommercial	noncommercial	ADJ
dpc-2053	6	30	use	use	NOUN
dpc-2053	6	31	,	,	PUNCT
dpc-2053	6	32	distribution	distribution	NOUN
dpc-2053	6	33	,	,	PUNCT
dpc-2053	6	34	and	and	CCONJ
dpc-2053	6	35	reproduction	reproduction	NOUN
dpc-2053	6	36	in	in	ADP
dpc-2053	6	37	any	any	DET
dpc-2053	6	38	medium	medium	NOUN
dpc-2053	6	39	,	,	PUNCT
dpc-2053	6	40	provided	provide	VERB
dpc-2053	6	41	the	the	DET
dpc-2053	6	42	original	original	ADJ
dpc-2053	6	43	authors	author	NOUN
dpc-2053	6	44	and	and	CCONJ
dpc-2053	6	45	source	source	NOUN
dpc-2053	6	46	are	be	AUX
dpc-2053	6	47	credited	credit	VERB
dpc-2053	6	48	.	.	PUNCT
dpc-2053	7	1	funding	funding	NOUN
dpc-2053	7	2	:	:	PUNCT
dpc-2053	7	3	none	none	NOUN
dpc-2053	7	4	.	.	PUNCT
dpc-2053	8	1	competing	compete	VERB
dpc-2053	8	2	interests	interest	NOUN
dpc-2053	8	3	:	:	PUNCT
dpc-2053	8	4	none	none	NOUN
dpc-2053	8	5	.	.	PUNCT
dpc-2053	9	1	authorship	authorship	NOUN
dpc-2053	9	2	:	:	PUNCT
dpc-2053	9	3	all	all	DET
dpc-2053	9	4	authors	author	NOUN
dpc-2053	9	5	have	have	AUX
dpc-2053	9	6	contributed	contribute	VERB
dpc-2053	9	7	significantly	significantly	ADV
dpc-2053	9	8	to	to	ADP
dpc-2053	9	9	this	this	DET
dpc-2053	9	10	publication	publication	NOUN
dpc-2053	9	11	.	.	PUNCT
dpc-2053	10	1	corresponding	correspond	VERB
dpc-2053	10	2	author	author	NOUN
dpc-2053	10	3	:	:	PUNCT
dpc-2053	10	4	francesca	francesca	PROPN
dpc-2053	10	5	pampaloni	pampaloni	NOUN
dpc-2053	10	6	,	,	PUNCT
dpc-2053	10	7	unit	unit	NOUN
dpc-2053	10	8	of	of	ADP
dpc-2053	10	9	dermatology	dermatology	NOUN
dpc-2053	10	10	,	,	PUNCT
dpc-2053	10	11	department	department	NOUN
dpc-2053	10	12	of	of	ADP
dpc-2053	10	13	medicine	medicine	NOUN
dpc-2053	10	14	(	(	PUNCT
dpc-2053	10	15	dimed	dimed	PROPN
dpc-2053	10	16	)	)	PUNCT
dpc-2053	10	17	,	,	PUNCT
dpc-2053	10	18	university	university	NOUN
dpc-2053	10	19	of	of	ADP
dpc-2053	10	20	padova	padova	PROPN
dpc-2053	10	21	,	,	PUNCT
dpc-2053	10	22	via	via	ADP
dpc-2053	10	23	gallucci	gallucci	PROPN
dpc-2053	10	24	4	4	NUM
dpc-2053	10	25	,	,	PUNCT
dpc-2053	10	26	35128	35128	NUM
dpc-2053	10	27	padua	padua	PROPN
dpc-2053	10	28	,	,	PUNCT
dpc-2053	10	29	italy	italy	PROPN
dpc-2053	10	30	.	.	PUNCT
dpc-2053	11	1	phone	phone	NOUN
dpc-2053	11	2	00390498212901	00390498212901	NUM
dpc-2053	11	3	e	e	NOUN
dpc-2053	11	4	-	-	NOUN
dpc-2053	11	5	mail	mail	NOUN
dpc-2053	11	6	:	:	PUNCT
dpc-2053	11	7	francesca.pampaloni@gmail.com	francesca.pampaloni@gmail.com	X
dpc-2053	11	8	introduction	introduction	NOUN
dpc-2053	11	9	:	:	PUNCT
dpc-2053	11	10	omalizumab	omalizumab	NOUN
dpc-2053	11	11	has	have	AUX
dpc-2053	11	12	been	be	AUX
dpc-2053	11	13	recently	recently	ADV
dpc-2053	11	14	registered	register	VERB
dpc-2053	11	15	as	as	ADP
dpc-2053	11	16	a	a	DET
dpc-2053	11	17	third	third	ADJ
dpc-2053	11	18	-	-	PUNCT
dpc-2053	11	19	line	line	NOUN
dpc-2053	11	20	therapy	therapy	NOUN
dpc-2053	11	21	for	for	ADP
dpc-2053	11	22	chronic	chronic	ADJ
dpc-2053	11	23	spontaneous	spontaneous	ADJ
dpc-2053	11	24	urticaria	urticaria	NOUN
dpc-2053	11	25	.	.	PUNCT
dpc-2053	12	1	objectives	objective	NOUN
dpc-2053	12	2	:	:	PUNCT
dpc-2053	12	3	in	in	ADP
dpc-2053	12	4	this	this	DET
dpc-2053	12	5	study	study	NOUN
dpc-2053	12	6	,	,	PUNCT
dpc-2053	12	7	we	we	PRON
dpc-2053	12	8	aimed	aim	VERB
dpc-2053	12	9	to	to	PART
dpc-2053	12	10	provide	provide	VERB
dpc-2053	12	11	real	real	ADJ
dpc-2053	12	12	life	life	NOUN
dpc-2053	12	13	data	datum	NOUN
dpc-2053	12	14	by	by	ADP
dpc-2053	12	15	reporting	report	VERB
dpc-2053	12	16	our	our	PRON
dpc-2053	12	17	experience	experience	NOUN
dpc-2053	12	18	with	with	ADP
dpc-2053	12	19	omalizumab	omalizumab	NOUN
dpc-2053	12	20	in	in	ADP
dpc-2053	12	21	the	the	DET
dpc-2053	12	22	treatment	treatment	NOUN
dpc-2053	12	23	of	of	ADP
dpc-2053	12	24	chronic	chronic	ADJ
dpc-2053	12	25	spontaneous	spontaneous	ADJ
dpc-2053	12	26	urticaria	urticaria	NOUN
dpc-2053	12	27	.	.	PUNCT
dpc-2053	13	1	methods	method	NOUN
dpc-2053	13	2	:	:	PUNCT
dpc-2053	13	3	a	a	DET
dpc-2053	13	4	retrospective	retrospective	ADJ
dpc-2053	13	5	data	data	NOUN
dpc-2053	13	6	analysis	analysis	NOUN
dpc-2053	13	7	was	be	AUX
dpc-2053	13	8	conducted	conduct	VERB
dpc-2053	13	9	on	on	ADP
dpc-2053	13	10	40	40	NUM
dpc-2053	13	11	patients	patient	NOUN
dpc-2053	13	12	affected	affect	VERB
dpc-2053	13	13	by	by	ADP
dpc-2053	13	14	chronic	chronic	ADJ
dpc-2053	13	15	spontaneous	spontaneous	ADJ
dpc-2053	13	16	urticaria	urticaria	NOUN
dpc-2053	13	17	and	and	CCONJ
dpc-2053	13	18	treated	treat	VERB
dpc-2053	13	19	with	with	ADP
dpc-2053	13	20	omalizumab	omalizumab	NOUN
dpc-2053	13	21	at	at	ADP
dpc-2053	13	22	the	the	DET
dpc-2053	13	23	dermatology	dermatology	NOUN
dpc-2053	13	24	unit	unit	NOUN
dpc-2053	13	25	of	of	ADP
dpc-2053	13	26	padova	padova	PROPN
dpc-2053	13	27	university	university	PROPN
dpc-2053	13	28	hospital	hospital	NOUN
dpc-2053	13	29	.	.	PUNCT
dpc-2053	14	1	demographic	demographic	ADJ
dpc-2053	14	2	,	,	PUNCT
dpc-2053	14	3	anthropometric	anthropometric	ADJ
dpc-2053	14	4	,	,	PUNCT
dpc-2053	14	5	and	and	CCONJ
dpc-2053	14	6	clinical	clinical	ADJ
dpc-2053	14	7	data	datum	NOUN
dpc-2053	14	8	have	have	AUX
dpc-2053	14	9	been	be	AUX
dpc-2053	14	10	collected	collect	VERB
dpc-2053	14	11	.	.	PUNCT
dpc-2053	15	1	results	result	NOUN
dpc-2053	15	2	:	:	PUNCT
dpc-2053	15	3	overall	overall	ADV
dpc-2053	15	4	,	,	PUNCT
dpc-2053	15	5	the	the	DET
dpc-2053	15	6	majority	majority	NOUN
dpc-2053	15	7	of	of	ADP
dpc-2053	15	8	patients	patient	NOUN
dpc-2053	15	9	(	(	PUNCT
dpc-2053	15	10	23	23	NUM
dpc-2053	15	11	patients	patient	NOUN
dpc-2053	15	12	,	,	PUNCT
dpc-2053	15	13	57.5	57.5	NUM
dpc-2053	15	14	%	%	NOUN
dpc-2053	15	15	)	)	PUNCT
dpc-2053	15	16	achieved	achieve	VERB
dpc-2053	15	17	complete	complete	ADJ
dpc-2053	15	18	recovery	recovery	NOUN
dpc-2053	15	19	by	by	ADP
dpc-2053	15	20	taking	take	VERB
dpc-2053	15	21	omalizumab	omalizumab	NOUN
dpc-2053	15	22	and	and	CCONJ
dpc-2053	15	23	17.5	17.5	NUM
dpc-2053	15	24	%	%	NOUN
dpc-2053	15	25	(	(	PUNCT
dpc-2053	15	26	7	7	NUM
dpc-2053	15	27	patients	patient	NOUN
dpc-2053	15	28	)	)	PUNCT
dpc-2053	15	29	had	have	VERB
dpc-2053	15	30	a	a	DET
dpc-2053	15	31	partial	partial	ADJ
dpc-2053	15	32	response	response	NOUN
dpc-2053	15	33	.	.	PUNCT
dpc-2053	16	1	the	the	DET
dpc-2053	16	2	majority	majority	NOUN
dpc-2053	16	3	of	of	ADP
dpc-2053	16	4	patients	patient	NOUN
dpc-2053	16	5	who	who	PRON
dpc-2053	16	6	did	do	AUX
dpc-2053	16	7	not	not	PART
dpc-2053	16	8	have	have	VERB
dpc-2053	16	9	a	a	DET
dpc-2053	16	10	response	response	NOUN
dpc-2053	16	11	to	to	ADP
dpc-2053	16	12	omalizumab	omalizumab	NOUN
dpc-2053	16	13	had	have	VERB
dpc-2053	16	14	a	a	DET
dpc-2053	16	15	body	body	NOUN
dpc-2053	16	16	mass	mass	NOUN
dpc-2053	16	17	index	index	NOUN
dpc-2053	16	18	(	(	PUNCT
dpc-2053	16	19	bmi	bmi	PROPN
dpc-2053	16	20	)	)	PUNCT
dpc-2053	16	21	>	>	X
dpc-2053	16	22	25	25	NUM
dpc-2053	16	23	kg	kg	NOUN
dpc-2053	16	24	/	/	SYM
dpc-2053	16	25	m2	m2	PROPN
dpc-2053	16	26	.	.	PUNCT
dpc-2053	17	1	conclusions	conclusion	NOUN
dpc-2053	17	2	:	:	PUNCT
dpc-2053	17	3	our	our	PRON
dpc-2053	17	4	study	study	NOUN
dpc-2053	17	5	suggests	suggest	VERB
dpc-2053	17	6	that	that	SCONJ
dpc-2053	17	7	omalizumab	omalizumab	NOUN
dpc-2053	17	8	is	be	AUX
dpc-2053	17	9	a	a	DET
dpc-2053	17	10	safe	safe	ADJ
dpc-2053	17	11	and	and	CCONJ
dpc-2053	17	12	effective	effective	ADJ
dpc-2053	17	13	treatment	treatment	NOUN
dpc-2053	17	14	for	for	ADP
dpc-2053	17	15	chronic	chronic	ADJ
dpc-2053	17	16	spontaneous	spontaneous	ADJ
dpc-2053	17	17	urticaria	urticaria	NOUN
dpc-2053	17	18	.	.	PUNCT
dpc-2053	18	1	we	we	PRON
dpc-2053	18	2	identified	identify	VERB
dpc-2053	18	3	bmi	bmi	NOUN
dpc-2053	18	4	as	as	ADP
dpc-2053	18	5	a	a	DET
dpc-2053	18	6	critical	critical	ADJ
dpc-2053	18	7	biological	biological	ADJ
dpc-2053	18	8	factor	factor	NOUN
dpc-2053	18	9	that	that	PRON
dpc-2053	18	10	significantly	significantly	ADV
dpc-2053	18	11	impacts	impact	VERB
dpc-2053	18	12	the	the	DET
dpc-2053	18	13	outcomes	outcome	NOUN
dpc-2053	18	14	of	of	ADP
dpc-2053	18	15	omalizumab	omalizumab	NOUN
dpc-2053	18	16	treatment	treatment	NOUN
dpc-2053	18	17	.	.	PUNCT
dpc-2053	19	1	our	our	PRON
dpc-2053	19	2	findings	finding	NOUN
dpc-2053	19	3	also	also	ADV
dpc-2053	19	4	suggest	suggest	VERB
dpc-2053	19	5	a	a	DET
dpc-2053	19	6	potential	potential	ADJ
dpc-2053	19	7	use	use	NOUN
dpc-2053	19	8	of	of	ADP
dpc-2053	19	9	bmi	bmi	NOUN
dpc-2053	19	10	as	as	ADP
dpc-2053	19	11	a	a	DET
dpc-2053	19	12	predictive	predictive	ADJ
dpc-2053	19	13	biomarker	biomarker	NOUN
dpc-2053	19	14	for	for	ADP
dpc-2053	19	15	omalizumab	omalizumab	NOUN
dpc-2053	19	16	treatment	treatment	NOUN
dpc-2053	19	17	.	.	PUNCT
dpc-2053	20	1	an	an	DET
dpc-2053	20	2	up	up	ADV
dpc-2053	20	3	-	-	PUNCT
dpc-2053	20	4	dosing	dosing	NOUN
dpc-2053	20	5	of	of	ADP
dpc-2053	20	6	omalizumab	omalizumab	NOUN
dpc-2053	20	7	may	may	AUX
dpc-2053	20	8	be	be	AUX
dpc-2053	20	9	proposed	propose	VERB
dpc-2053	20	10	in	in	ADP
dpc-2053	20	11	patients	patient	NOUN
dpc-2053	20	12	with	with	ADP
dpc-2053	20	13	high	high	ADJ
dpc-2053	20	14	bmi	bmi	NOUN
dpc-2053	20	15	to	to	PART
dpc-2053	20	16	achieve	achieve	VERB
dpc-2053	20	17	a	a	DET
dpc-2053	20	18	better	well	ADJ
dpc-2053	20	19	control	control	NOUN
dpc-2053	20	20	of	of	ADP
dpc-2053	20	21	the	the	DET
dpc-2053	20	22	disease	disease	NOUN
dpc-2053	20	23	.	.	PUNCT
dpc-2053	21	1	abstract	abstract	ADJ
dpc-2053	21	2	2	2	NUM
dpc-2053	21	3	original	original	ADJ
dpc-2053	21	4	article	article	NOUN
dpc-2053	21	5	|	|	ADV
dpc-2053	21	6	dermatol	dermatol	ADJ
dpc-2053	21	7	pract	pract	NOUN
dpc-2053	21	8	concept	concept	NOUN
dpc-2053	21	9	.	.	PUNCT
dpc-2053	22	1	2022;12(4):e2022148	2022;12(4):e2022148	NUM
dpc-2053	22	2	introduction	introduction	NOUN
dpc-2053	22	3	chronic	chronic	ADJ
dpc-2053	22	4	spontaneous	spontaneous	ADJ
dpc-2053	22	5	urticaria	urticaria	NOUN
dpc-2053	22	6	(	(	PUNCT
dpc-2053	22	7	csu	csu	PROPN
dpc-2053	22	8	)	)	PUNCT
dpc-2053	22	9	is	be	AUX
dpc-2053	22	10	a	a	DET
dpc-2053	22	11	common	common	ADJ
dpc-2053	22	12	disease	disease	NOUN
dpc-2053	22	13	,	,	PUNCT
dpc-2053	22	14	however	however	ADV
dpc-2053	22	15	,	,	PUNCT
dpc-2053	22	16	epidemiological	epidemiological	ADJ
dpc-2053	22	17	data	datum	NOUN
dpc-2053	22	18	currently	currently	ADV
dpc-2053	22	19	available	available	ADJ
dpc-2053	22	20	on	on	ADP
dpc-2053	22	21	csu	csu	PROPN
dpc-2053	22	22	prevalence	prevalence	NOUN
dpc-2053	22	23	ranging	range	VERB
dpc-2053	22	24	from	from	ADP
dpc-2053	22	25	0.02	0.02	NUM
dpc-2053	22	26	%	%	NOUN
dpc-2053	22	27	to	to	PART
dpc-2053	22	28	1	1	NUM
dpc-2053	22	29	%	%	NOUN
dpc-2053	22	30	in	in	ADP
dpc-2053	22	31	different	different	ADJ
dpc-2053	22	32	studies	study	NOUN
dpc-2053	22	33	[	[	X
dpc-2053	22	34	1,2	1,2	NUM
dpc-2053	22	35	]	]	PUNCT
dpc-2053	22	36	.	.	PUNCT
dpc-2053	23	1	it	it	PRON
dpc-2053	23	2	is	be	AUX
dpc-2053	23	3	clinically	clinically	ADV
dpc-2053	23	4	characterized	characterize	VERB
dpc-2053	23	5	by	by	ADP
dpc-2053	23	6	the	the	DET
dpc-2053	23	7	recurrent	recurrent	ADJ
dpc-2053	23	8	appearance	appearance	NOUN
dpc-2053	23	9	of	of	ADP
dpc-2053	23	10	itch	itch	NOUN
dpc-2053	23	11	,	,	PUNCT
dpc-2053	23	12	wheals	wheal	NOUN
dpc-2053	23	13	and/or	and/or	CCONJ
dpc-2053	23	14	angioedema	angioedema	VERB
dpc-2053	23	15	for	for	ADP
dpc-2053	23	16	more	more	ADJ
dpc-2053	23	17	than	than	ADP
dpc-2053	23	18	6	6	NUM
dpc-2053	23	19	 	 	SPACE
dpc-2053	23	20	weeks	week	NOUN
dpc-2053	23	21	in	in	ADP
dpc-2053	23	22	absence	absence	NOUN
dpc-2053	23	23	of	of	ADP
dpc-2053	23	24	a	a	DET
dpc-2053	23	25	known	know	VERB
dpc-2053	23	26	trigger	trigger	NOUN
dpc-2053	23	27	[	[	X
dpc-2053	23	28	3	3	NUM
dpc-2053	23	29	]	]	PUNCT
dpc-2053	23	30	.	.	PUNCT
dpc-2053	24	1	it	it	PRON
dpc-2053	24	2	is	be	AUX
dpc-2053	24	3	often	often	ADV
dpc-2053	24	4	a	a	DET
dpc-2053	24	5	self	self	NOUN
dpc-2053	24	6	limiting	limit	VERB
dpc-2053	24	7	disease	disease	NOUN
dpc-2053	24	8	lasting	last	VERB
dpc-2053	24	9	no	no	DET
dpc-2053	24	10	more	more	ADJ
dpc-2053	24	11	than	than	ADP
dpc-2053	24	12	2	2	NUM
dpc-2053	24	13	-	-	SYM
dpc-2053	24	14	5	5	NUM
dpc-2053	24	15	years	year	NOUN
dpc-2053	24	16	;	;	PUNCT
dpc-2053	24	17	however	however	ADV
dpc-2053	24	18	in	in	ADP
dpc-2053	24	19	20	20	NUM
dpc-2053	24	20	%	%	NOUN
dpc-2053	24	21	of	of	ADP
dpc-2053	24	22	patients	patient	NOUN
dpc-2053	24	23	lasts	last	VERB
dpc-2053	24	24	for	for	ADP
dpc-2053	24	25	more	more	ADJ
dpc-2053	24	26	than	than	ADP
dpc-2053	24	27	5	5	NUM
dpc-2053	24	28	years	year	NOUN
dpc-2053	24	29	.	.	PUNCT
dpc-2053	25	1	many	many	ADJ
dpc-2053	25	2	factors	factor	NOUN
dpc-2053	25	3	may	may	AUX
dpc-2053	25	4	play	play	VERB
dpc-2053	25	5	a	a	DET
dpc-2053	25	6	role	role	NOUN
dpc-2053	25	7	in	in	ADP
dpc-2053	25	8	the	the	DET
dpc-2053	25	9	pathogenesis	pathogenesis	NOUN
dpc-2053	25	10	of	of	ADP
dpc-2053	25	11	chronic	chronic	ADJ
dpc-2053	25	12	idiopathic	idiopathic	ADJ
dpc-2053	25	13	urticaria	urticaria	NOUN
dpc-2053	25	14	,	,	PUNCT
dpc-2053	25	15	including	include	VERB
dpc-2053	25	16	infections	infection	NOUN
dpc-2053	25	17	,	,	PUNCT
dpc-2053	25	18	diet	diet	NOUN
dpc-2053	25	19	,	,	PUNCT
dpc-2053	25	20	drugs	drug	NOUN
dpc-2053	25	21	,	,	PUNCT
dpc-2053	25	22	emotional	emotional	ADJ
dpc-2053	25	23	factors	factor	NOUN
dpc-2053	25	24	,	,	PUNCT
dpc-2053	25	25	and	and	CCONJ
dpc-2053	25	26	stress	stress	NOUN
dpc-2053	25	27	[	[	X
dpc-2053	25	28	1,4	1,4	NUM
dpc-2053	25	29	]	]	PUNCT
dpc-2053	25	30	.	.	PUNCT
dpc-2053	26	1	chronic	chronic	ADJ
dpc-2053	26	2	spontaneous	spontaneous	ADJ
dpc-2053	26	3	urticaria	urticaria	NOUN
dpc-2053	26	4	highly	highly	ADV
dpc-2053	26	5	impacts	impact	VERB
dpc-2053	26	6	quality	quality	NOUN
dpc-2053	26	7	of	of	ADP
dpc-2053	26	8	life	life	NOUN
dpc-2053	26	9	of	of	ADP
dpc-2053	26	10	patients	patient	NOUN
dpc-2053	26	11	affected	affect	VERB
dpc-2053	26	12	.	.	PUNCT
dpc-2053	27	1	pruritus	pruritus	PROPN
dpc-2053	27	2	causes	cause	VERB
dpc-2053	27	3	variable	variable	ADJ
dpc-2053	27	4	discomfort	discomfort	NOUN
dpc-2053	27	5	,	,	PUNCT
dpc-2053	27	6	as	as	ADV
dpc-2053	27	7	well	well	ADV
dpc-2053	27	8	as	as	ADP
dpc-2053	27	9	cutaneous	cutaneous	ADJ
dpc-2053	27	10	wheals	wheal	NOUN
dpc-2053	27	11	which	which	PRON
dpc-2053	27	12	may	may	AUX
dpc-2053	27	13	harm	harm	VERB
dpc-2053	27	14	individual	individual	ADJ
dpc-2053	27	15	physical	physical	ADJ
dpc-2053	27	16	appearance	appearance	NOUN
dpc-2053	27	17	and	and	CCONJ
dpc-2053	27	18	social	social	ADJ
dpc-2053	27	19	life	life	NOUN
dpc-2053	27	20	.	.	PUNCT
dpc-2053	28	1	the	the	DET
dpc-2053	28	2	first	first	ADJ
dpc-2053	28	3	line	line	NOUN
dpc-2053	28	4	therapy	therapy	NOUN
dpc-2053	28	5	for	for	ADP
dpc-2053	28	6	csu	csu	PROPN
dpc-2053	28	7	consists	consist	VERB
dpc-2053	28	8	in	in	ADP
dpc-2053	28	9	the	the	DET
dpc-2053	28	10	use	use	NOUN
dpc-2053	28	11	of	of	ADP
dpc-2053	28	12	non	non	ADJ
dpc-2053	28	13	-	-	ADJ
dpc-2053	28	14	sedating	sedating	ADJ
dpc-2053	28	15	h1	h1	NOUN
dpc-2053	28	16	-	-	PUNCT
dpc-2053	28	17	antihistamines	antihistamine	NOUN
dpc-2053	28	18	.	.	PUNCT
dpc-2053	29	1	if	if	SCONJ
dpc-2053	29	2	the	the	DET
dpc-2053	29	3	response	response	NOUN
dpc-2053	29	4	is	be	AUX
dpc-2053	29	5	inadequate	inadequate	ADJ
dpc-2053	29	6	after	after	ADP
dpc-2053	29	7	two	two	NUM
dpc-2053	29	8	weeks	week	NOUN
dpc-2053	29	9	of	of	ADP
dpc-2053	29	10	treatment	treatment	NOUN
dpc-2053	29	11	,	,	PUNCT
dpc-2053	29	12	increasing	increase	VERB
dpc-2053	29	13	the	the	DET
dpc-2053	29	14	antihistamine	antihistamine	NOUN
dpc-2053	29	15	dosage	dosage	NOUN
dpc-2053	29	16	up	up	ADP
dpc-2053	29	17	to	to	PART
dpc-2053	29	18	four	four	NUM
dpc-2053	29	19	-	-	ADJ
dpc-2053	29	20	fold	fold	NOUN
dpc-2053	29	21	is	be	AUX
dpc-2053	29	22	recommended	recommend	VERB
dpc-2053	29	23	as	as	ADP
dpc-2053	29	24	second	second	ADJ
dpc-2053	29	25	-	-	PUNCT
dpc-2053	29	26	line	line	NOUN
dpc-2053	29	27	therapy	therapy	NOUN
dpc-2053	29	28	[	[	X
dpc-2053	29	29	2,4	2,4	NUM
dpc-2053	29	30	]	]	PUNCT
dpc-2053	29	31	.	.	PUNCT
dpc-2053	30	1	omalizumab	omalizumab	NOUN
dpc-2053	30	2	,	,	PUNCT
dpc-2053	30	3	a	a	DET
dpc-2053	30	4	humanized	humanize	VERB
dpc-2053	30	5	anti	anti	ADJ
dpc-2053	30	6	-	-	ADJ
dpc-2053	30	7	ige	ige	ADJ
dpc-2053	30	8	monoclonal	monoclonal	NOUN
dpc-2053	30	9	antibody	antibody	NOUN
dpc-2053	30	10	,	,	PUNCT
dpc-2053	30	11	that	that	PRON
dpc-2053	30	12	was	be	AUX
dpc-2053	30	13	primarily	primarily	ADV
dpc-2053	30	14	approved	approve	VERB
dpc-2053	30	15	for	for	ADP
dpc-2053	30	16	the	the	DET
dpc-2053	30	17	treatment	treatment	NOUN
dpc-2053	30	18	of	of	ADP
dpc-2053	30	19	moderate/	moderate/	ADV
dpc-2053	30	20	severe	severe	ADJ
dpc-2053	30	21	asthma	asthma	NOUN
dpc-2053	30	22	has	have	AUX
dpc-2053	30	23	been	be	AUX
dpc-2053	30	24	recently	recently	ADV
dpc-2053	30	25	registered	register	VERB
dpc-2053	30	26	for	for	ADP
dpc-2053	30	27	csu	csu	NOUN
dpc-2053	30	28	treatment	treatment	NOUN
dpc-2053	30	29	as	as	ADP
dpc-2053	30	30	a	a	DET
dpc-2053	30	31	third	third	ADJ
dpc-2053	30	32	-	-	PUNCT
dpc-2053	30	33	line	line	NOUN
dpc-2053	30	34	therapy	therapy	NOUN
dpc-2053	30	35	[	[	X
dpc-2053	30	36	5	5	NUM
dpc-2053	30	37	-	-	SYM
dpc-2053	30	38	8	8	NUM
dpc-2053	30	39	]	]	PUNCT
dpc-2053	30	40	.	.	PUNCT
dpc-2053	31	1	objectives	objective	NOUN
dpc-2053	31	2	in	in	ADP
dpc-2053	31	3	this	this	DET
dpc-2053	31	4	study	study	NOUN
dpc-2053	31	5	,	,	PUNCT
dpc-2053	31	6	we	we	PRON
dpc-2053	31	7	aimed	aim	VERB
dpc-2053	31	8	to	to	PART
dpc-2053	31	9	provide	provide	VERB
dpc-2053	31	10	real	real	ADJ
dpc-2053	31	11	life	life	NOUN
dpc-2053	31	12	data	datum	NOUN
dpc-2053	31	13	by	by	ADP
dpc-2053	31	14	reporting	report	VERB
dpc-2053	31	15	our	our	PRON
dpc-2053	31	16	experience	experience	NOUN
dpc-2053	31	17	with	with	ADP
dpc-2053	31	18	omalizumab	omalizumab	NOUN
dpc-2053	31	19	in	in	ADP
dpc-2053	31	20	the	the	DET
dpc-2053	31	21	treatment	treatment	NOUN
dpc-2053	31	22	of	of	ADP
dpc-2053	31	23	csu	csu	PROPN
dpc-2053	31	24	.	.	PUNCT
dpc-2053	32	1	methods	method	NOUN
dpc-2053	32	2	a	a	DET
dpc-2053	32	3	retrospective	retrospective	ADJ
dpc-2053	32	4	data	data	NOUN
dpc-2053	32	5	analysis	analysis	NOUN
dpc-2053	32	6	was	be	AUX
dpc-2053	32	7	conducted	conduct	VERB
dpc-2053	32	8	on	on	ADP
dpc-2053	32	9	40	40	NUM
dpc-2053	32	10	patients	patient	NOUN
dpc-2053	32	11	affected	affect	VERB
dpc-2053	32	12	by	by	ADP
dpc-2053	32	13	csu	csu	PROPN
dpc-2053	32	14	and	and	CCONJ
dpc-2053	32	15	treated	treat	VERB
dpc-2053	32	16	with	with	ADP
dpc-2053	32	17	omalizumab	omalizumab	NOUN
dpc-2053	32	18	between	between	ADP
dpc-2053	32	19	2016	2016	NUM
dpc-2053	32	20	and	and	CCONJ
dpc-2053	32	21	2019	2019	NUM
dpc-2053	32	22	at	at	ADP
dpc-2053	32	23	the	the	DET
dpc-2053	32	24	dermatology	dermatology	NOUN
dpc-2053	32	25	unit	unit	NOUN
dpc-2053	32	26	of	of	ADP
dpc-2053	32	27	padova	padova	PROPN
dpc-2053	32	28	university	university	PROPN
dpc-2053	32	29	hospital	hospital	NOUN
dpc-2053	32	30	.	.	PUNCT
dpc-2053	33	1	all	all	DET
dpc-2053	33	2	patients	patient	NOUN
dpc-2053	33	3	provided	provide	VERB
dpc-2053	33	4	written	write	VERB
dpc-2053	33	5	informed	inform	VERB
dpc-2053	33	6	consent	consent	NOUN
dpc-2053	33	7	.	.	PUNCT
dpc-2053	34	1	the	the	DET
dpc-2053	34	2	patients	patient	NOUN
dpc-2053	34	3	included	include	VERB
dpc-2053	34	4	were	be	AUX
dpc-2053	34	5	aged	age	VERB
dpc-2053	34	6	over	over	ADP
dpc-2053	34	7	than	than	ADP
dpc-2053	34	8	18	18	NUM
dpc-2053	34	9	years	year	NOUN
dpc-2053	34	10	with	with	ADP
dpc-2053	34	11	at	at	ADV
dpc-2053	34	12	least	least	ADV
dpc-2053	34	13	6	6	NUM
dpc-2053	34	14	 	 	SPACE
dpc-2053	34	15	months	month	NOUN
dpc-2053	34	16	history	history	NOUN
dpc-2053	34	17	of	of	ADP
dpc-2053	34	18	chronic	chronic	ADJ
dpc-2053	34	19	idiopathic	idiopathic	ADJ
dpc-2053	34	20	urticaria	urticaria	NOUN
dpc-2053	34	21	.	.	PUNCT
dpc-2053	35	1	the	the	DET
dpc-2053	35	2	severity	severity	NOUN
dpc-2053	35	3	of	of	ADP
dpc-2053	35	4	the	the	DET
dpc-2053	35	5	urticaria	urticaria	NOUN
dpc-2053	35	6	was	be	AUX
dpc-2053	35	7	assessed	assess	VERB
dpc-2053	35	8	thanks	thank	NOUN
dpc-2053	35	9	to	to	ADP
dpc-2053	35	10	the	the	DET
dpc-2053	35	11	urticaria	urticaria	NOUN
dpc-2053	35	12	activity	activity	NOUN
dpc-2053	35	13	score	score	NOUN
dpc-2053	35	14	(	(	PUNCT
dpc-2053	35	15	uas	uas	NOUN
dpc-2053	35	16	)	)	PUNCT
dpc-2053	35	17	and	and	CCONJ
dpc-2053	35	18	established	establish	VERB
dpc-2053	35	19	both	both	CCONJ
dpc-2053	35	20	daily	daily	ADJ
dpc-2053	35	21	and	and	CCONJ
dpc-2053	35	22	weekly	weekly	ADJ
dpc-2053	35	23	(	(	PUNCT
dpc-2053	35	24	uas7	uas7	PROPN
dpc-2053	35	25	)	)	PUNCT
dpc-2053	35	26	,	,	PUNCT
dpc-2053	35	27	based	base	VERB
dpc-2053	35	28	on	on	ADP
dpc-2053	35	29	the	the	DET
dpc-2053	35	30	presence	presence	NOUN
dpc-2053	35	31	of	of	ADP
dpc-2053	35	32	wheals	wheal	NOUN
dpc-2053	35	33	and	and	CCONJ
dpc-2053	35	34	itching	itching	NOUN
dpc-2053	35	35	.	.	PUNCT
dpc-2053	36	1	all	all	DET
dpc-2053	36	2	patients	patient	NOUN
dpc-2053	36	3	received	receive	VERB
dpc-2053	36	4	a	a	DET
dpc-2053	36	5	300	300	NUM
dpc-2053	36	6	mg	mg	NOUN
dpc-2053	36	7	subcutaneous	subcutaneous	ADJ
dpc-2053	36	8	injection	injection	NOUN
dpc-2053	36	9	of	of	ADP
dpc-2053	36	10	omalizumab	omalizumab	NOUN
dpc-2053	36	11	every	every	DET
dpc-2053	36	12	4	4	NUM
dpc-2053	36	13	weeks	week	NOUN
dpc-2053	36	14	for	for	ADP
dpc-2053	36	15	at	at	ADV
dpc-2053	36	16	least	least	ADV
dpc-2053	36	17	6	6	NUM
dpc-2053	36	18	months	month	NOUN
dpc-2053	36	19	.	.	PUNCT
dpc-2053	37	1	once	once	ADV
dpc-2053	37	2	a	a	DET
dpc-2053	37	3	month	month	NOUN
dpc-2053	37	4	,	,	PUNCT
dpc-2053	37	5	follow	follow	VERB
dpc-2053	37	6	-	-	PUNCT
dpc-2053	37	7	up	up	ADP
dpc-2053	37	8	visits	visit	NOUN
dpc-2053	37	9	were	be	AUX
dpc-2053	37	10	scheduled	schedule	VERB
dpc-2053	37	11	together	together	ADV
dpc-2053	37	12	with	with	ADP
dpc-2053	37	13	the	the	DET
dpc-2053	37	14	omalizumab	omalizumab	NOUN
dpc-2053	37	15	infusions	infusion	NOUN
dpc-2053	37	16	.	.	PUNCT
dpc-2053	38	1	the	the	DET
dpc-2053	38	2	following	follow	VERB
dpc-2053	38	3	data	datum	NOUN
dpc-2053	38	4	were	be	AUX
dpc-2053	38	5	collected	collect	VERB
dpc-2053	38	6	:	:	PUNCT
dpc-2053	38	7	birth	birth	NOUN
dpc-2053	38	8	date	date	NOUN
dpc-2053	38	9	,	,	PUNCT
dpc-2053	38	10	sex	sex	NOUN
dpc-2053	38	11	,	,	PUNCT
dpc-2053	38	12	height	height	NOUN
dpc-2053	38	13	,	,	PUNCT
dpc-2053	38	14	weight	weight	NOUN
dpc-2053	38	15	,	,	PUNCT
dpc-2053	38	16	date	date	NOUN
dpc-2053	38	17	of	of	ADP
dpc-2053	38	18	urticaria	urticaria	NOUN
dpc-2053	38	19	diagnosis	diagnosis	NOUN
dpc-2053	38	20	,	,	PUNCT
dpc-2053	38	21	severity	severity	NOUN
dpc-2053	38	22	of	of	ADP
dpc-2053	38	23	the	the	DET
dpc-2053	38	24	disease	disease	NOUN
dpc-2053	38	25	,	,	PUNCT
dpc-2053	38	26	previous	previous	ADJ
dpc-2053	38	27	urticaria	urticaria	NOUN
dpc-2053	38	28	therapies	therapy	NOUN
dpc-2053	38	29	,	,	PUNCT
dpc-2053	38	30	comorbidities	comorbiditie	NOUN
dpc-2053	38	31	,	,	PUNCT
dpc-2053	38	32	and	and	CCONJ
dpc-2053	38	33	concomitant	concomitant	ADJ
dpc-2053	38	34	medications	medication	NOUN
dpc-2053	38	35	.	.	PUNCT
dpc-2053	39	1	the	the	DET
dpc-2053	39	2	body	body	NOUN
dpc-2053	39	3	mass	mass	PROPN
dpc-2053	39	4	index	index	NOUN
dpc-2053	39	5	(	(	PUNCT
dpc-2053	39	6	bmi	bmi	PROPN
dpc-2053	39	7	)	)	PUNCT
dpc-2053	39	8	value	value	NOUN
dpc-2053	39	9	was	be	AUX
dpc-2053	39	10	calculated	calculate	VERB
dpc-2053	39	11	(	(	PUNCT
dpc-2053	39	12	in	in	ADP
dpc-2053	39	13	kg	kg	PROPN
dpc-2053	39	14	/	/	SYM
dpc-2053	39	15	m2	m2	PROPN
dpc-2053	39	16	)	)	PUNCT
dpc-2053	39	17	to	to	PART
dpc-2053	39	18	classify	classify	VERB
dpc-2053	39	19	patients	patient	NOUN
dpc-2053	39	20	as	as	ADP
dpc-2053	39	21	underweight	underweight	NOUN
dpc-2053	39	22	(	(	PUNCT
dpc-2053	39	23	bmi	bmi	X
dpc-2053	39	24	<	<	X
dpc-2053	39	25	18.4	18.4	NUM
dpc-2053	39	26	kg	kg	NOUN
dpc-2053	39	27	/	/	SYM
dpc-2053	39	28	m2	m2	PROPN
dpc-2053	39	29	)	)	PUNCT
dpc-2053	39	30	,	,	PUNCT
dpc-2053	39	31	normal	normal	ADJ
dpc-2053	39	32	weight	weight	NOUN
dpc-2053	39	33	(	(	PUNCT
dpc-2053	39	34	18.5	18.5	NUM
dpc-2053	39	35	kg	kg	NOUN
dpc-2053	39	36	/	/	SYM
dpc-2053	39	37	m2≤	m2≤	PROPN
dpc-2053	39	38	bmi	bmi	NOUN
dpc-2053	39	39	≤	≤	NUM
dpc-2053	39	40	24.9	24.9	NUM
dpc-2053	39	41	kg	kg	NOUN
dpc-2053	39	42	/	/	SYM
dpc-2053	39	43	m2	m2	PROPN
dpc-2053	39	44	)	)	PUNCT
dpc-2053	39	45	,	,	PUNCT
dpc-2053	39	46	overweight	overweight	NOUN
dpc-2053	39	47	(	(	PUNCT
dpc-2053	39	48	25	25	NUM
dpc-2053	39	49	kg	kg	NOUN
dpc-2053	39	50	/	/	SYM
dpc-2053	39	51	m2≤	m2≤	NUM
dpc-2053	39	52	bmi	bmi	NOUN
dpc-2053	39	53	≤	≤	NUM
dpc-2053	39	54	29.9	29.9	NUM
dpc-2053	39	55	kg	kg	NOUN
dpc-2053	39	56	/	/	SYM
dpc-2053	39	57	m2	m2	PROPN
dpc-2053	39	58	)	)	PUNCT
dpc-2053	39	59	and	and	CCONJ
dpc-2053	39	60	obese	obese	NOUN
dpc-2053	39	61	(	(	PUNCT
dpc-2053	39	62	bmi	bmi	X
dpc-2053	39	63	≥	≥	NUM
dpc-2053	39	64	30	30	NUM
dpc-2053	39	65	kg	kg	NOUN
dpc-2053	39	66	/	/	SYM
dpc-2053	39	67	m2	m2	PROPN
dpc-2053	39	68	)	)	PUNCT
dpc-2053	39	69	.	.	PUNCT
dpc-2053	40	1	the	the	DET
dpc-2053	40	2	date	date	NOUN
dpc-2053	40	3	of	of	ADP
dpc-2053	40	4	the	the	DET
dpc-2053	40	5	first	first	ADJ
dpc-2053	40	6	omalizumab	omalizumab	NOUN
dpc-2053	40	7	administration	administration	NOUN
dpc-2053	40	8	,	,	PUNCT
dpc-2053	40	9	the	the	DET
dpc-2053	40	10	number	number	NOUN
dpc-2053	40	11	of	of	ADP
dpc-2053	40	12	therapy	therapy	NOUN
dpc-2053	40	13	cycles	cycle	NOUN
dpc-2053	40	14	and	and	CCONJ
dpc-2053	40	15	the	the	DET
dpc-2053	40	16	date	date	NOUN
dpc-2053	40	17	of	of	ADP
dpc-2053	40	18	the	the	DET
dpc-2053	40	19	last	last	ADJ
dpc-2053	40	20	infusion	infusion	NOUN
dpc-2053	40	21	were	be	AUX
dpc-2053	40	22	recorded	record	VERB
dpc-2053	40	23	as	as	ADV
dpc-2053	40	24	well	well	ADV
dpc-2053	40	25	as	as	ADP
dpc-2053	40	26	any	any	DET
dpc-2053	40	27	adverse	adverse	ADJ
dpc-2053	40	28	events	event	NOUN
dpc-2053	40	29	during	during	ADP
dpc-2053	40	30	or	or	CCONJ
dpc-2053	40	31	after	after	ADP
dpc-2053	40	32	omalizumab	omalizumab	NOUN
dpc-2053	40	33	administration	administration	NOUN
dpc-2053	40	34	.	.	PUNCT
dpc-2053	41	1	the	the	DET
dpc-2053	41	2	outcome	outcome	NOUN
dpc-2053	41	3	of	of	ADP
dpc-2053	41	4	the	the	DET
dpc-2053	41	5	treatment	treatment	NOUN
dpc-2053	41	6	with	with	ADP
dpc-2053	41	7	omalizumab	omalizumab	NOUN
dpc-2053	41	8	was	be	AUX
dpc-2053	41	9	evaluated	evaluate	VERB
dpc-2053	41	10	based	base	VERB
dpc-2053	41	11	on	on	ADP
dpc-2053	41	12	the	the	DET
dpc-2053	41	13	patient	patient	NOUN
dpc-2053	41	14	’s	’s	PART
dpc-2053	41	15	report	report	NOUN
dpc-2053	41	16	,	,	PUNCT
dpc-2053	41	17	any	any	DET
dpc-2053	41	18	objective	objective	ADJ
dpc-2053	41	19	improvement	improvement	NOUN
dpc-2053	41	20	or	or	CCONJ
dpc-2053	41	21	worsening	worsening	NOUN
dpc-2053	41	22	,	,	PUNCT
dpc-2053	41	23	and	and	CCONJ
dpc-2053	41	24	reduction	reduction	NOUN
dpc-2053	41	25	of	of	ADP
dpc-2053	41	26	uas7	uas7	PROPN
dpc-2053	41	27	.	.	PUNCT
dpc-2053	42	1	uas7=0	uas7=0	PROPN
dpc-2053	42	2	was	be	AUX
dpc-2053	42	3	considered	consider	VERB
dpc-2053	42	4	as	as	ADP
dpc-2053	42	5	complete	complete	ADJ
dpc-2053	42	6	response	response	NOUN
dpc-2053	42	7	,	,	PUNCT
dpc-2053	42	8	while	while	SCONJ
dpc-2053	42	9	a	a	DET
dpc-2053	42	10	90	90	NUM
dpc-2053	42	11	%	%	NOUN
dpc-2053	42	12	reduction	reduction	NOUN
dpc-2053	42	13	in	in	ADP
dpc-2053	42	14	uas7	uas7	NOUN
dpc-2053	42	15	was	be	AUX
dpc-2053	42	16	considered	consider	VERB
dpc-2053	42	17	as	as	ADP
dpc-2053	42	18	a	a	DET
dpc-2053	42	19	partial	partial	ADJ
dpc-2053	42	20	response	response	NOUN
dpc-2053	42	21	.	.	PUNCT
dpc-2053	43	1	benefit	benefit	NOUN
dpc-2053	43	2	achieved	achieve	VERB
dpc-2053	43	3	after	after	ADP
dpc-2053	43	4	a	a	DET
dpc-2053	43	5	single	single	ADJ
dpc-2053	43	6	course	course	NOUN
dpc-2053	43	7	of	of	ADP
dpc-2053	43	8	omalizumab	omalizumab	NOUN
dpc-2053	43	9	was	be	AUX
dpc-2053	43	10	considered	consider	VERB
dpc-2053	43	11	a	a	DET
dpc-2053	43	12	partial	partial	ADJ
dpc-2053	43	13	response	response	NOUN
dpc-2053	43	14	.	.	PUNCT
dpc-2053	44	1	results	result	VERB
dpc-2053	44	2	the	the	DET
dpc-2053	44	3	study	study	NOUN
dpc-2053	44	4	included	include	VERB
dpc-2053	44	5	40	40	NUM
dpc-2053	44	6	patients	patient	NOUN
dpc-2053	44	7	with	with	ADP
dpc-2053	44	8	the	the	DET
dpc-2053	44	9	following	follow	VERB
dpc-2053	44	10	demographic	demographic	ADJ
dpc-2053	44	11	characteristics	characteristic	NOUN
dpc-2053	44	12	:	:	PUNCT
dpc-2053	44	13	30	30	NUM
dpc-2053	44	14	females	female	NOUN
dpc-2053	44	15	(	(	PUNCT
dpc-2053	44	16	75	75	NUM
dpc-2053	44	17	%	%	NOUN
dpc-2053	44	18	)	)	PUNCT
dpc-2053	44	19	and	and	CCONJ
dpc-2053	44	20	10	10	NUM
dpc-2053	44	21	males	male	NOUN
dpc-2053	44	22	(	(	PUNCT
dpc-2053	44	23	25	25	NUM
dpc-2053	44	24	%	%	NOUN
dpc-2053	44	25	)	)	PUNCT
dpc-2053	44	26	,	,	PUNCT
dpc-2053	44	27	with	with	ADP
dpc-2053	44	28	a	a	DET
dpc-2053	44	29	mean	mean	ADJ
dpc-2053	44	30	age	age	NOUN
dpc-2053	44	31	of	of	ADP
dpc-2053	44	32	49	49	NUM
dpc-2053	44	33	years	year	NOUN
dpc-2053	44	34	(	(	PUNCT
dpc-2053	44	35	range	range	NOUN
dpc-2053	44	36	:	:	PUNCT
dpc-2053	44	37	2181	2181	NUM
dpc-2053	44	38	years	year	NOUN
dpc-2053	44	39	)	)	PUNCT
dpc-2053	44	40	.	.	PUNCT
dpc-2053	45	1	the	the	DET
dpc-2053	45	2	minimum	minimum	ADJ
dpc-2053	45	3	bmi	bmi	NOUN
dpc-2053	45	4	detected	detect	VERB
dpc-2053	45	5	was	be	AUX
dpc-2053	45	6	17.8	17.8	NUM
dpc-2053	45	7	kg	kg	NOUN
dpc-2053	45	8	/	/	SYM
dpc-2053	45	9	m2	m2	PROPN
dpc-2053	45	10	,	,	PUNCT
dpc-2053	45	11	while	while	SCONJ
dpc-2053	45	12	the	the	DET
dpc-2053	45	13	maximum	maximum	NOUN
dpc-2053	45	14	was	be	AUX
dpc-2053	45	15	34	34	NUM
dpc-2053	45	16	kg	kg	NOUN
dpc-2053	45	17	/	/	SYM
dpc-2053	45	18	m2	m2	PROPN
dpc-2053	45	19	,	,	PUNCT
dpc-2053	45	20	with	with	ADP
dpc-2053	45	21	an	an	DET
dpc-2053	45	22	average	average	ADJ
dpc-2053	45	23	value	value	NOUN
dpc-2053	45	24	of	of	ADP
dpc-2053	45	25	24.1	24.1	NUM
dpc-2053	45	26	kg	kg	NOUN
dpc-2053	45	27	/	/	SYM
dpc-2053	45	28	m2	m2	PROPN
dpc-2053	45	29	.	.	PUNCT
dpc-2053	46	1	the	the	DET
dpc-2053	46	2	patients	patient	NOUN
dpc-2053	46	3	were	be	AUX
dpc-2053	46	4	divided	divide	VERB
dpc-2053	46	5	in	in	ADP
dpc-2053	46	6	underweight	underweight	NOUN
dpc-2053	46	7	,	,	PUNCT
dpc-2053	46	8	normal	normal	ADJ
dpc-2053	46	9	weight	weight	NOUN
dpc-2053	46	10	,	,	PUNCT
dpc-2053	46	11	overweight	overweight	NOUN
dpc-2053	46	12	and	and	CCONJ
dpc-2053	46	13	obese	obese	ADJ
dpc-2053	46	14	(	(	PUNCT
dpc-2053	46	15	table	table	NOUN
dpc-2053	46	16	1	1	NUM
dpc-2053	46	17	)	)	PUNCT
dpc-2053	46	18	.	.	PUNCT
dpc-2053	47	1	the	the	DET
dpc-2053	47	2	date	date	NOUN
dpc-2053	47	3	of	of	ADP
dpc-2053	47	4	urticaria	urticaria	ADJ
dpc-2053	47	5	diagnosis	diagnosis	NOUN
dpc-2053	47	6	was	be	AUX
dpc-2053	47	7	between	between	ADP
dpc-2053	47	8	1994	1994	NUM
dpc-2053	47	9	and	and	CCONJ
dpc-2053	47	10	2019	2019	NUM
dpc-2053	47	11	.	.	PUNCT
dpc-2053	48	1	the	the	DET
dpc-2053	48	2	mean	mean	ADJ
dpc-2053	48	3	age	age	NOUN
dpc-2053	48	4	of	of	ADP
dpc-2053	48	5	patients	patient	NOUN
dpc-2053	48	6	at	at	ADP
dpc-2053	48	7	the	the	DET
dpc-2053	48	8	time	time	NOUN
dpc-2053	48	9	of	of	ADP
dpc-2053	48	10	the	the	DET
dpc-2053	48	11	diagnosis	diagnosis	NOUN
dpc-2053	48	12	was	be	AUX
dpc-2053	48	13	45	45	NUM
dpc-2053	48	14	years	year	NOUN
dpc-2053	48	15	.	.	PUNCT
dpc-2053	49	1	all	all	DET
dpc-2053	49	2	patients	patient	NOUN
dpc-2053	49	3	were	be	AUX
dpc-2053	49	4	affected	affect	VERB
dpc-2053	49	5	by	by	ADP
dpc-2053	49	6	severe	severe	ADJ
dpc-2053	49	7	disease	disease	NOUN
dpc-2053	49	8	with	with	ADP
dpc-2053	49	9	uas	uas	PROPN
dpc-2053	49	10	>	>	X
dpc-2053	49	11	4	4	NUM
dpc-2053	49	12	and	and	CCONJ
dpc-2053	49	13	uas7	uas7	NOUN
dpc-2053	49	14	>	>	X
dpc-2053	49	15	30	30	NUM
dpc-2053	49	16	before	before	ADP
dpc-2053	49	17	starting	start	VERB
dpc-2053	49	18	treatment	treatment	NOUN
dpc-2053	49	19	with	with	ADP
dpc-2053	49	20	omalizumab	omalizumab	NOUN
dpc-2053	49	21	.	.	PUNCT
dpc-2053	50	1	medications	medication	NOUN
dpc-2053	50	2	used	use	VERB
dpc-2053	50	3	before	before	ADP
dpc-2053	50	4	omalizumab	omalizumab	NOUN
dpc-2053	50	5	for	for	ADP
dpc-2053	50	6	the	the	DET
dpc-2053	50	7	treatment	treatment	NOUN
dpc-2053	50	8	of	of	ADP
dpc-2053	50	9	csu	csu	PROPN
dpc-2053	50	10	included	include	VERB
dpc-2053	50	11	three	three	NUM
dpc-2053	50	12	main	main	ADJ
dpc-2053	50	13	classes	class	NOUN
dpc-2053	50	14	of	of	ADP
dpc-2053	50	15	drugs	drug	NOUN
dpc-2053	50	16	:	:	PUNCT
dpc-2053	50	17	antihistamines	antihistamine	NOUN
dpc-2053	50	18	(	(	PUNCT
dpc-2053	50	19	85	85	NUM
dpc-2053	50	20	%	%	NOUN
dpc-2053	50	21	of	of	ADP
dpc-2053	50	22	patients	patient	NOUN
dpc-2053	50	23	,	,	PUNCT
dpc-2053	50	24	mainly	mainly	ADV
dpc-2053	50	25	desloratadine	desloratadine	NOUN
dpc-2053	50	26	)	)	PUNCT
dpc-2053	50	27	,	,	PUNCT
dpc-2053	50	28	glucocorticoids	glucocorticoid	NOUN
dpc-2053	50	29	(	(	PUNCT
dpc-2053	50	30	62.5	62.5	NUM
dpc-2053	50	31	%	%	NOUN
dpc-2053	50	32	of	of	ADP
dpc-2053	50	33	patients	patient	NOUN
dpc-2053	50	34	,	,	PUNCT
dpc-2053	50	35	mostly	mostly	ADV
dpc-2053	50	36	prednisone	prednisone	VERB
dpc-2053	50	37	)	)	PUNCT
dpc-2053	50	38	and	and	CCONJ
dpc-2053	50	39	immunosuppressants	immunosuppressant	NOUN
dpc-2053	50	40	(	(	PUNCT
dpc-2053	50	41	27.5	27.5	NUM
dpc-2053	50	42	%	%	NOUN
dpc-2053	50	43	of	of	ADP
dpc-2053	50	44	patients	patient	NOUN
dpc-2053	50	45	,	,	PUNCT
dpc-2053	50	46	primarily	primarily	ADV
dpc-2053	50	47	cyclosporine	cyclosporine	NOUN
dpc-2053	50	48	)	)	PUNCT
dpc-2053	50	49	.	.	PUNCT
dpc-2053	51	1	furthermore	furthermore	ADV
dpc-2053	51	2	,	,	PUNCT
dpc-2053	51	3	27.5	27.5	NUM
dpc-2053	51	4	%	%	NOUN
dpc-2053	51	5	of	of	ADP
dpc-2053	51	6	patients	patient	NOUN
dpc-2053	51	7	followed	follow	VERB
dpc-2053	51	8	a	a	DET
dpc-2053	51	9	histamine	histamine	NOUN
dpc-2053	51	10	-	-	PUNCT
dpc-2053	51	11	free	free	ADJ
dpc-2053	51	12	diet	diet	NOUN
dpc-2053	51	13	,	,	PUNCT
dpc-2053	51	14	10	10	NUM
dpc-2053	51	15	%	%	NOUN
dpc-2053	51	16	of	of	ADP
dpc-2053	51	17	cases	case	NOUN
dpc-2053	51	18	received	receive	VERB
dpc-2053	51	19	a	a	DET
dpc-2053	51	20	supplementation	supplementation	NOUN
dpc-2053	51	21	with	with	ADP
dpc-2053	51	22	nicotinamide	nicotinamide	NOUN
dpc-2053	51	23	,	,	PUNCT
dpc-2053	51	24	while	while	SCONJ
dpc-2053	51	25	5	5	NUM
dpc-2053	51	26	%	%	NOUN
dpc-2053	51	27	of	of	ADP
dpc-2053	51	28	patients	patient	NOUN
dpc-2053	51	29	were	be	AUX
dpc-2053	51	30	treated	treat	VERB
dpc-2053	51	31	with	with	ADP
dpc-2053	51	32	uvb	uvb	ADJ
dpc-2053	51	33	phototherapy	phototherapy	NOUN
dpc-2053	51	34	.	.	PUNCT
dpc-2053	52	1	the	the	DET
dpc-2053	52	2	majority	majority	NOUN
dpc-2053	52	3	of	of	ADP
dpc-2053	52	4	patients	patient	NOUN
dpc-2053	52	5	(	(	PUNCT
dpc-2053	52	6	80	80	NUM
dpc-2053	52	7	%	%	NOUN
dpc-2053	52	8	)	)	PUNCT
dpc-2053	52	9	presented	present	VERB
dpc-2053	52	10	comorbidities	comorbiditie	NOUN
dpc-2053	52	11	including	include	VERB
dpc-2053	52	12	allergic	allergic	ADJ
dpc-2053	52	13	rhinitis	rhinitis	NOUN
dpc-2053	52	14	(	(	PUNCT
dpc-2053	52	15	20	20	NUM
dpc-2053	52	16	%	%	NOUN
dpc-2053	52	17	)	)	PUNCT
dpc-2053	52	18	,	,	PUNCT
dpc-2053	52	19	hypothyroidism	hypothyroidism	NOUN
dpc-2053	52	20	(	(	PUNCT
dpc-2053	52	21	20	20	NUM
dpc-2053	52	22	%	%	NOUN
dpc-2053	52	23	)	)	PUNCT
dpc-2053	52	24	,	,	PUNCT
dpc-2053	52	25	nickel	nickel	NOUN
dpc-2053	52	26	allergy	allergy	NOUN
dpc-2053	52	27	(	(	PUNCT
dpc-2053	52	28	15	15	NUM
dpc-2053	52	29	%	%	NOUN
dpc-2053	52	30	)	)	PUNCT
dpc-2053	52	31	,	,	PUNCT
dpc-2053	52	32	grasses	grass	VERB
dpc-2053	52	33	allergy	allergy	NOUN
dpc-2053	52	34	(	(	PUNCT
dpc-2053	52	35	12.5	12.5	NUM
dpc-2053	52	36	%	%	NOUN
dpc-2053	52	37	)	)	PUNCT
dpc-2053	52	38	and	and	CCONJ
dpc-2053	52	39	atopic	atopic	NOUN
dpc-2053	52	40	dermatitis	dermatitis	NOUN
dpc-2053	52	41	table	table	NOUN
dpc-2053	52	42	1	1	NUM
dpc-2053	52	43	.	.	PUNCT
dpc-2053	53	1	classification	classification	NOUN
dpc-2053	53	2	of	of	ADP
dpc-2053	53	3	patients	patient	NOUN
dpc-2053	53	4	based	base	VERB
dpc-2053	53	5	on	on	ADP
dpc-2053	53	6	the	the	DET
dpc-2053	53	7	bmi	bmi	PROPN
dpc-2053	53	8	value	value	NOUN
dpc-2053	53	9	according	accord	VERB
dpc-2053	53	10	to	to	ADP
dpc-2053	53	11	the	the	DET
dpc-2053	53	12	who	who	PRON
dpc-2053	53	13	:	:	PUNCT
dpc-2053	53	14	underweight	underweight	NOUN
dpc-2053	53	15	(	(	PUNCT
dpc-2053	53	16	<	<	X
dpc-2053	53	17	18.5	18.5	NUM
dpc-2053	53	18	kg	kg	NOUN
dpc-2053	53	19	/	/	SYM
dpc-2053	53	20	m2	m2	PROPN
dpc-2053	53	21	)	)	PUNCT
dpc-2053	53	22	,	,	PUNCT
dpc-2053	53	23	normal	normal	ADJ
dpc-2053	53	24	weight	weight	NOUN
dpc-2053	53	25	(	(	PUNCT
dpc-2053	53	26	18.524.9	18.524.9	NUM
dpc-2053	53	27	kg	kg	NOUN
dpc-2053	53	28	/	/	SYM
dpc-2053	53	29	m2	m2	PROPN
dpc-2053	53	30	)	)	PUNCT
dpc-2053	53	31	,	,	PUNCT
dpc-2053	53	32	overweight	overweight	NOUN
dpc-2053	53	33	(	(	PUNCT
dpc-2053	53	34	2529.9	2529.9	NUM
dpc-2053	53	35	kg	kg	NOUN
dpc-2053	53	36	/	/	SYM
dpc-2053	53	37	m2	m2	PROPN
dpc-2053	53	38	)	)	PUNCT
dpc-2053	53	39	and	and	CCONJ
dpc-2053	53	40	obese	obese	NOUN
dpc-2053	53	41	(	(	PUNCT
dpc-2053	53	42	>	>	SYM
dpc-2053	53	43	30	30	NUM
dpc-2053	53	44	kg	kg	NOUN
dpc-2053	53	45	/	/	SYM
dpc-2053	53	46	m2	m2	PROPN
dpc-2053	53	47	)	)	PUNCT
dpc-2053	53	48	patient	patient	ADJ
dpc-2053	53	49	underweight	underweight	NOUN
dpc-2053	53	50	normal	normal	ADJ
dpc-2053	53	51	weight	weight	NOUN
dpc-2053	53	52	overweight	overweight	NOUN
dpc-2053	53	53	obese	obese	ADJ
dpc-2053	53	54	female	female	NOUN
dpc-2053	53	55	,	,	PUNCT
dpc-2053	53	56	n	n	CCONJ
dpc-2053	53	57	(	(	PUNCT
dpc-2053	53	58	%	%	INTJ
dpc-2053	53	59	)	)	PUNCT
dpc-2053	53	60	2	2	NUM
dpc-2053	53	61	(	(	PUNCT
dpc-2053	53	62	5	5	NUM
dpc-2053	53	63	%	%	NOUN
dpc-2053	53	64	)	)	PUNCT
dpc-2053	53	65	17	17	NUM
dpc-2053	53	66	(	(	PUNCT
dpc-2053	53	67	42,5	42,5	NUM
dpc-2053	53	68	%	%	NOUN
dpc-2053	53	69	)	)	PUNCT
dpc-2053	53	70	7	7	NUM
dpc-2053	53	71	(	(	PUNCT
dpc-2053	53	72	17,5	17,5	NUM
dpc-2053	53	73	%	%	NOUN
dpc-2053	53	74	)	)	PUNCT
dpc-2053	53	75	4	4	NUM
dpc-2053	53	76	(	(	PUNCT
dpc-2053	53	77	10	10	NUM
dpc-2053	53	78	%	%	NOUN
dpc-2053	53	79	)	)	PUNCT
dpc-2053	53	80	male	male	NOUN
dpc-2053	53	81	,	,	PUNCT
dpc-2053	53	82	n	n	CCONJ
dpc-2053	53	83	(	(	PUNCT
dpc-2053	53	84	%	%	NOUN
dpc-2053	53	85	)	)	PUNCT
dpc-2053	53	86	0	0	NUM
dpc-2053	53	87	6	6	NUM
dpc-2053	53	88	(	(	PUNCT
dpc-2053	53	89	15	15	NUM
dpc-2053	53	90	%	%	NOUN
dpc-2053	53	91	)	)	PUNCT
dpc-2053	53	92	4	4	NUM
dpc-2053	53	93	(	(	PUNCT
dpc-2053	53	94	10	10	NUM
dpc-2053	53	95	%	%	NOUN
dpc-2053	53	96	)	)	PUNCT
dpc-2053	53	97	0	0	NUM
dpc-2053	54	1	original	original	ADJ
dpc-2053	54	2	article	article	NOUN
dpc-2053	54	3	|	|	ADV
dpc-2053	54	4	dermatol	dermatol	ADJ
dpc-2053	54	5	pract	pract	NOUN
dpc-2053	54	6	concept	concept	NOUN
dpc-2053	54	7	.	.	PUNCT
dpc-2053	55	1	2022;12(4):e2022148	2022;12(4):e2022148	NUM
dpc-2053	55	2	3	3	NUM
dpc-2053	55	3	(	(	PUNCT
dpc-2053	55	4	12.5	12.5	NUM
dpc-2053	55	5	%	%	NOUN
dpc-2053	55	6	)	)	PUNCT
dpc-2053	55	7	were	be	AUX
dpc-2053	55	8	detected	detect	VERB
dpc-2053	55	9	.	.	PUNCT
dpc-2053	56	1	simultaneously	simultaneously	ADV
dpc-2053	56	2	to	to	ADP
dpc-2053	56	3	the	the	DET
dpc-2053	56	4	omalizumab	omalizumab	NOUN
dpc-2053	56	5	therapy	therapy	NOUN
dpc-2053	56	6	,	,	PUNCT
dpc-2053	56	7	many	many	ADJ
dpc-2053	56	8	patients	patient	NOUN
dpc-2053	56	9	have	have	AUX
dpc-2053	56	10	taken	take	VERB
dpc-2053	56	11	various	various	ADJ
dpc-2053	56	12	therapies	therapy	NOUN
dpc-2053	56	13	for	for	ADP
dpc-2053	56	14	both	both	DET
dpc-2053	56	15	csu	csu	PROPN
dpc-2053	56	16	and	and	CCONJ
dpc-2053	56	17	their	their	PRON
dpc-2053	56	18	concurrent	concurrent	ADJ
dpc-2053	56	19	diseases	disease	NOUN
dpc-2053	56	20	including	include	VERB
dpc-2053	56	21	antihistamines	antihistamine	NOUN
dpc-2053	56	22	(	(	PUNCT
dpc-2053	56	23	60	60	NUM
dpc-2053	56	24	%	%	NOUN
dpc-2053	56	25	)	)	PUNCT
dpc-2053	56	26	,	,	PUNCT
dpc-2053	56	27	glucocorticoids	glucocorticoid	NOUN
dpc-2053	56	28	(	(	PUNCT
dpc-2053	56	29	55	55	NUM
dpc-2053	56	30	%	%	NOUN
dpc-2053	56	31	)	)	PUNCT
dpc-2053	56	32	,	,	PUNCT
dpc-2053	56	33	levothyroxine	levothyroxine	PROPN
dpc-2053	56	34	(	(	PUNCT
dpc-2053	56	35	15	15	NUM
dpc-2053	56	36	%	%	NOUN
dpc-2053	56	37	)	)	PUNCT
dpc-2053	56	38	.	.	PUNCT
dpc-2053	57	1	in	in	ADP
dpc-2053	57	2	addition	addition	NOUN
dpc-2053	57	3	,	,	PUNCT
dpc-2053	57	4	15	15	NUM
dpc-2053	57	5	%	%	NOUN
dpc-2053	57	6	of	of	ADP
dpc-2053	57	7	patients	patient	NOUN
dpc-2053	57	8	continued	continue	VERB
dpc-2053	57	9	to	to	PART
dpc-2053	57	10	follow	follow	VERB
dpc-2053	57	11	a	a	DET
dpc-2053	57	12	histamine	histamine	NOUN
dpc-2053	57	13	-	-	PUNCT
dpc-2053	57	14	free	free	ADJ
dpc-2053	57	15	diet	diet	NOUN
dpc-2053	57	16	and	and	CCONJ
dpc-2053	57	17	12.5	12.5	NUM
dpc-2053	57	18	%	%	NOUN
dpc-2053	57	19	were	be	AUX
dpc-2053	57	20	taking	take	VERB
dpc-2053	57	21	nicotinamide	nicotinamide	NOUN
dpc-2053	57	22	.	.	PUNCT
dpc-2053	58	1	overall	overall	ADJ
dpc-2053	58	2	,	,	PUNCT
dpc-2053	58	3	30	30	NUM
dpc-2053	58	4	patients	patient	NOUN
dpc-2053	58	5	(	(	PUNCT
dpc-2053	58	6	75	75	NUM
dpc-2053	58	7	%	%	NOUN
dpc-2053	58	8	)	)	PUNCT
dpc-2053	58	9	completed	complete	VERB
dpc-2053	58	10	the	the	DET
dpc-2053	58	11	entire	entire	ADJ
dpc-2053	58	12	course	course	NOUN
dpc-2053	58	13	of	of	ADP
dpc-2053	58	14	omalizumab	omalizumab	NOUN
dpc-2053	58	15	therapy	therapy	NOUN
dpc-2053	58	16	,	,	PUNCT
dpc-2053	58	17	while	while	SCONJ
dpc-2053	58	18	10	10	NUM
dpc-2053	58	19	of	of	ADP
dpc-2053	58	20	them	they	PRON
dpc-2053	58	21	(	(	PUNCT
dpc-2053	58	22	25	25	NUM
dpc-2053	58	23	%	%	NOUN
dpc-2053	58	24	)	)	PUNCT
dpc-2053	58	25	discontinued	discontinue	VERB
dpc-2053	58	26	omalizumab	omalizumab	NOUN
dpc-2053	58	27	due	due	ADP
dpc-2053	58	28	to	to	ADP
dpc-2053	58	29	acute	acute	ADJ
dpc-2053	58	30	side	side	NOUN
dpc-2053	58	31	effects	effect	NOUN
dpc-2053	58	32	(	(	PUNCT
dpc-2053	58	33	discontinuation	discontinuation	NOUN
dpc-2053	58	34	at	at	ADP
dpc-2053	58	35	the	the	DET
dpc-2053	58	36	first	first	ADJ
dpc-2053	58	37	dose	dose	NOUN
dpc-2053	58	38	,	,	PUNCT
dpc-2053	58	39	in	in	ADP
dpc-2053	58	40	2	2	NUM
dpc-2053	58	41	patients	patient	NOUN
dpc-2053	58	42	)	)	PUNCT
dpc-2053	58	43	,	,	PUNCT
dpc-2053	58	44	other	other	ADJ
dpc-2053	58	45	diseases	disease	NOUN
dpc-2053	58	46	(	(	PUNCT
dpc-2053	58	47	2	2	NUM
dpc-2053	58	48	patients	patient	NOUN
dpc-2053	58	49	)	)	PUNCT
dpc-2053	58	50	or	or	CCONJ
dpc-2053	58	51	ineffectiveness	ineffectiveness	NOUN
dpc-2053	58	52	(	(	PUNCT
dpc-2053	58	53	6	6	NUM
dpc-2053	58	54	patients	patient	NOUN
dpc-2053	58	55	)	)	PUNCT
dpc-2053	58	56	.	.	PUNCT
dpc-2053	59	1	based	base	VERB
dpc-2053	59	2	on	on	ADP
dpc-2053	59	3	the	the	DET
dpc-2053	59	4	results	result	NOUN
dpc-2053	59	5	obtained	obtain	VERB
dpc-2053	59	6	,	,	PUNCT
dpc-2053	59	7	patients	patient	NOUN
dpc-2053	59	8	were	be	AUX
dpc-2053	59	9	classified	classify	VERB
dpc-2053	59	10	into	into	ADP
dpc-2053	59	11	three	three	NUM
dpc-2053	59	12	categories	category	NOUN
dpc-2053	59	13	:	:	PUNCT
dpc-2053	59	14	no	no	DET
dpc-2053	59	15	response	response	NOUN
dpc-2053	59	16	(	(	PUNCT
dpc-2053	59	17	10	10	NUM
dpc-2053	59	18	cases	case	NOUN
dpc-2053	59	19	,	,	PUNCT
dpc-2053	59	20	25	25	NUM
dpc-2053	59	21	%	%	NOUN
dpc-2053	59	22	)	)	PUNCT
dpc-2053	59	23	,	,	PUNCT
dpc-2053	59	24	partial	partial	ADJ
dpc-2053	59	25	response	response	NOUN
dpc-2053	59	26	(	(	PUNCT
dpc-2053	59	27	7	7	NUM
dpc-2053	59	28	patients	patient	NOUN
dpc-2053	59	29	,	,	PUNCT
dpc-2053	59	30	17.5	17.5	NUM
dpc-2053	59	31	%	%	NOUN
dpc-2053	59	32	)	)	PUNCT
dpc-2053	59	33	,	,	PUNCT
dpc-2053	59	34	complete	complete	ADJ
dpc-2053	59	35	response	response	NOUN
dpc-2053	59	36	(	(	PUNCT
dpc-2053	59	37	23	23	NUM
dpc-2053	59	38	patients	patient	NOUN
dpc-2053	59	39	,	,	PUNCT
dpc-2053	59	40	57.5	57.5	NUM
dpc-2053	59	41	%	%	NOUN
dpc-2053	59	42	)	)	PUNCT
dpc-2053	59	43	(	(	PUNCT
dpc-2053	59	44	figure	figure	NOUN
dpc-2053	59	45	1	1	NUM
dpc-2053	59	46	)	)	PUNCT
dpc-2053	59	47	.	.	PUNCT
dpc-2053	60	1	the	the	DET
dpc-2053	60	2	majority	majority	NOUN
dpc-2053	60	3	of	of	ADP
dpc-2053	60	4	patients	patient	NOUN
dpc-2053	60	5	who	who	PRON
dpc-2053	60	6	did	do	AUX
dpc-2053	60	7	not	not	PART
dpc-2053	60	8	have	have	VERB
dpc-2053	60	9	a	a	DET
dpc-2053	60	10	response	response	NOUN
dpc-2053	60	11	to	to	ADP
dpc-2053	60	12	omalizumab	omalizumab	NOUN
dpc-2053	60	13	had	have	VERB
dpc-2053	60	14	a	a	DET
dpc-2053	60	15	bmi	bmi	NOUN
dpc-2053	60	16	>	>	X
dpc-2053	60	17	25	25	NUM
dpc-2053	60	18	kg	kg	PROPN
dpc-2053	60	19	/	/	SYM
dpc-2053	60	20	m2	m2	PROPN
dpc-2053	60	21	.	.	PUNCT
dpc-2053	61	1	binomial	binomial	ADJ
dpc-2053	61	2	logistic	logistic	ADJ
dpc-2053	61	3	regression	regression	NOUN
dpc-2053	61	4	enables	enable	VERB
dpc-2053	61	5	us	we	PRON
dpc-2053	61	6	to	to	PART
dpc-2053	61	7	determine	determine	VERB
dpc-2053	61	8	which	which	PRON
dpc-2053	61	9	of	of	ADP
dpc-2053	61	10	our	our	PRON
dpc-2053	61	11	independent	independent	ADJ
dpc-2053	61	12	variables	variable	NOUN
dpc-2053	61	13	have	have	VERB
dpc-2053	61	14	statistically	statistically	ADV
dpc-2053	61	15	significant	significant	ADJ
dpc-2053	61	16	effect	effect	NOUN
dpc-2053	61	17	on	on	ADP
dpc-2053	61	18	outcome	outcome	NOUN
dpc-2053	61	19	;	;	PUNCT
dpc-2053	61	20	considering	consider	VERB
dpc-2053	61	21	age	age	NOUN
dpc-2053	61	22	,	,	PUNCT
dpc-2053	61	23	sex	sex	NOUN
dpc-2053	61	24	and	and	CCONJ
dpc-2053	61	25	bmi	bmi	NOUN
dpc-2053	61	26	as	as	ADP
dpc-2053	61	27	variables	variable	NOUN
dpc-2053	61	28	,	,	PUNCT
dpc-2053	61	29	emerged	emerge	VERB
dpc-2053	61	30	that	that	SCONJ
dpc-2053	61	31	bmi	bmi	PROPN
dpc-2053	61	32	has	have	VERB
dpc-2053	61	33	a	a	DET
dpc-2053	61	34	statistically	statistically	ADV
dpc-2053	61	35	significant	significant	ADJ
dpc-2053	61	36	effect	effect	NOUN
dpc-2053	61	37	(	(	PUNCT
dpc-2053	61	38	p	p	X
dpc-2053	61	39	=	=	NOUN
dpc-2053	61	40	0.042	0.042	NUM
dpc-2053	61	41	)	)	PUNCT
dpc-2053	61	42	,	,	PUNCT
dpc-2053	61	43	and	and	CCONJ
dpc-2053	61	44	odds	odd	NOUN
dpc-2053	61	45	ratio	ratio	NOUN
dpc-2053	61	46	<	<	X
dpc-2053	61	47	1	1	NUM
dpc-2053	61	48	indicates	indicate	VERB
dpc-2053	61	49	a	a	DET
dpc-2053	61	50	positive	positive	ADJ
dpc-2053	61	51	predictive	predictive	ADJ
dpc-2053	61	52	value	value	NOUN
dpc-2053	61	53	of	of	ADP
dpc-2053	61	54	better	well	ADJ
dpc-2053	61	55	response	response	NOUN
dpc-2053	61	56	to	to	ADP
dpc-2053	61	57	therapy	therapy	NOUN
dpc-2053	61	58	(	(	PUNCT
dpc-2053	61	59	table	table	NOUN
dpc-2053	61	60	2	2	NUM
dpc-2053	61	61	)	)	PUNCT
dpc-2053	61	62	.	.	PUNCT
dpc-2053	62	1	conclusions	conclusion	NOUN
dpc-2053	62	2	in	in	ADP
dpc-2053	62	3	our	our	PRON
dpc-2053	62	4	cohort	cohort	NOUN
dpc-2053	62	5	patients	patient	NOUN
dpc-2053	62	6	were	be	AUX
dpc-2053	62	7	predominantly	predominantly	ADV
dpc-2053	62	8	female	female	ADJ
dpc-2053	62	9	(	(	PUNCT
dpc-2053	62	10	m	m	NUM
dpc-2053	62	11	:	:	PUNCT
dpc-2053	62	12	f	f	X
dpc-2053	62	13	ratio	ratio	NOUN
dpc-2053	62	14	was	be	AUX
dpc-2053	62	15	1:3	1:3	NUM
dpc-2053	62	16	)	)	PUNCT
dpc-2053	62	17	,	,	PUNCT
dpc-2053	62	18	according	accord	VERB
dpc-2053	62	19	to	to	ADP
dpc-2053	62	20	the	the	DET
dpc-2053	62	21	literature	literature	NOUN
dpc-2053	62	22	,	,	PUNCT
dpc-2053	62	23	which	which	PRON
dpc-2053	62	24	reports	report	VERB
dpc-2053	62	25	a	a	DET
dpc-2053	62	26	prevalence	prevalence	NOUN
dpc-2053	62	27	of	of	ADP
dpc-2053	62	28	csu	csu	PROPN
dpc-2053	62	29	two	two	NUM
dpc-2053	62	30	times	time	NOUN
dpc-2053	62	31	higher	high	ADJ
dpc-2053	62	32	among	among	ADP
dpc-2053	62	33	women	woman	NOUN
dpc-2053	62	34	than	than	ADP
dpc-2053	62	35	man	man	NOUN
dpc-2053	62	36	.	.	PUNCT
dpc-2053	63	1	it	it	PRON
dpc-2053	63	2	may	may	AUX
dpc-2053	63	3	be	be	AUX
dpc-2053	63	4	explained	explain	VERB
dpc-2053	63	5	by	by	ADP
dpc-2053	63	6	the	the	DET
dpc-2053	63	7	role	role	NOUN
dpc-2053	63	8	of	of	ADP
dpc-2053	63	9	autoimmunity	autoimmunity	NOUN
dpc-2053	63	10	in	in	ADP
dpc-2053	63	11	csu	csu	PROPN
dpc-2053	63	12	60	60	NUM
dpc-2053	63	13	%	%	NOUN
dpc-2053	63	14	50	50	NUM
dpc-2053	63	15	%	%	NOUN
dpc-2053	63	16	40	40	NUM
dpc-2053	63	17	%	%	NOUN
dpc-2053	63	18	30	30	NUM
dpc-2053	63	19	%	%	NOUN
dpc-2053	63	20	20	20	NUM
dpc-2053	63	21	%	%	NOUN
dpc-2053	63	22	10	10	NUM
dpc-2053	63	23	%	%	NOUN
dpc-2053	63	24	0	0	NUM
dpc-2053	63	25	%	%	NOUN
dpc-2053	64	1	no	no	DET
dpc-2053	64	2	response	response	NOUN
dpc-2053	64	3	25	25	NUM
dpc-2053	64	4	%	%	NOUN
dpc-2053	64	5	17.5	17.5	NUM
dpc-2053	64	6	%	%	NOUN
dpc-2053	64	7	57.5	57.5	NUM
dpc-2053	64	8	%	%	NOUN
dpc-2053	64	9	no	no	DET
dpc-2053	64	10	response	response	NOUN
dpc-2053	64	11	partial	partial	ADJ
dpc-2053	64	12	response	response	NOUN
dpc-2053	64	13	outcome	outcome	NOUN
dpc-2053	64	14	to	to	PART
dpc-2053	64	15	omalizumab	omalizumab	VERB
dpc-2053	64	16	treatment	treatment	NOUN
dpc-2053	64	17	partial	partial	ADJ
dpc-2053	64	18	response	response	NOUN
dpc-2053	64	19	complete	complete	ADJ
dpc-2053	64	20	response	response	NOUN
dpc-2053	64	21	complete	complete	ADJ
dpc-2053	64	22	response	response	NOUN
dpc-2053	64	23	figure	figure	NOUN
dpc-2053	64	24	1	1	NUM
dpc-2053	64	25	.	.	PUNCT
dpc-2053	65	1	outcome	outcome	NOUN
dpc-2053	65	2	of	of	ADP
dpc-2053	65	3	omalizumab	omalizumab	NOUN
dpc-2053	65	4	treatment	treatment	NOUN
dpc-2053	65	5	.	.	PUNCT
dpc-2053	66	1	complete	complete	ADJ
dpc-2053	66	2	response	response	NOUN
dpc-2053	66	3	:	:	PUNCT
dpc-2053	67	1	uas7=0	uas7=0	ADP
dpc-2053	67	2	;	;	PUNCT
dpc-2053	67	3	partial	partial	ADJ
dpc-2053	67	4	response	response	NOUN
dpc-2053	67	5	:	:	PUNCT
dpc-2053	67	6	90	90	NUM
dpc-2053	67	7	%	%	NOUN
dpc-2053	67	8	reduction	reduction	NOUN
dpc-2053	67	9	of	of	ADP
dpc-2053	67	10	uas7	uas7	PROPN
dpc-2053	67	11	values	value	NOUN
dpc-2053	67	12	;	;	PUNCT
dpc-2053	67	13	25	25	NUM
dpc-2053	67	14	%	%	NOUN
dpc-2053	67	15	of	of	ADP
dpc-2053	67	16	patients	patient	NOUN
dpc-2053	67	17	(	(	PUNCT
dpc-2053	67	18	10	10	NUM
dpc-2053	67	19	patients	patient	NOUN
dpc-2053	67	20	)	)	PUNCT
dpc-2053	67	21	had	have	VERB
dpc-2053	67	22	no	no	DET
dpc-2053	67	23	response	response	NOUN
dpc-2053	67	24	;	;	PUNCT
dpc-2053	67	25	17.5	17.5	NUM
dpc-2053	67	26	%	%	NOUN
dpc-2053	67	27	of	of	ADP
dpc-2053	67	28	patients	patient	NOUN
dpc-2053	67	29	(	(	PUNCT
dpc-2053	67	30	7	7	NUM
dpc-2053	67	31	patients	patient	NOUN
dpc-2053	67	32	)	)	PUNCT
dpc-2053	67	33	reported	report	VERB
dpc-2053	67	34	partial	partial	ADJ
dpc-2053	67	35	response	response	NOUN
dpc-2053	67	36	,	,	PUNCT
dpc-2053	67	37	while	while	SCONJ
dpc-2053	67	38	57.5	57.5	NUM
dpc-2053	67	39	%	%	NOUN
dpc-2053	67	40	(	(	PUNCT
dpc-2053	67	41	23	23	NUM
dpc-2053	67	42	patients	patient	NOUN
dpc-2053	67	43	)	)	PUNCT
dpc-2053	67	44	had	have	VERB
dpc-2053	67	45	a	a	DET
dpc-2053	67	46	complete	complete	ADJ
dpc-2053	67	47	response	response	NOUN
dpc-2053	67	48	to	to	ADP
dpc-2053	67	49	omalizumab	omalizumab	NOUN
dpc-2053	67	50	.	.	PUNCT
dpc-2053	68	1	table	table	NOUN
dpc-2053	68	2	2	2	NUM
dpc-2053	68	3	.	.	PUNCT
dpc-2053	68	4	model	model	NOUN
dpc-2053	68	5	coefficients	coefficient	NOUN
dpc-2053	68	6	–	–	PUNCT
dpc-2053	68	7	outcome	outcome	NOUN
dpc-2053	68	8	predictor	predictor	NOUN
dpc-2053	68	9	estimatea	estimatea	PROPN
dpc-2053	69	1	se	se	PROPN
dpc-2053	69	2	z	z	PROPN
dpc-2053	70	1	p	p	NOUN
dpc-2053	70	2	odds	odd	NOUN
dpc-2053	70	3	ratio	ratio	NOUN
dpc-2053	70	4	intercept	intercept	NOUN
dpc-2053	70	5	3.8904	3.8904	NUM
dpc-2053	70	6	2.5292	2.5292	NUM
dpc-2053	70	7	1.538	1.538	NUM
dpc-2053	70	8	0.124	0.124	NUM
dpc-2053	70	9	48.930	48.930	NUM
dpc-2053	70	10	bmi	bmi	NOUN
dpc-2053	70	11	-0.2105	-0.2105	NOUN
dpc-2053	70	12	0.1037	0.1037	NUM
dpc-2053	70	13	-2.029	-2.029	PROPN
dpc-2053	70	14	0.042	0.042	NUM
dpc-2053	70	15	0.810	0.810	NUM
dpc-2053	70	16	age	age	NOUN
dpc-2053	70	17	0.0458	0.0458	NUM
dpc-2053	70	18	0.0315	0.0315	NUM
dpc-2053	70	19	1.452	1.452	NUM
dpc-2053	70	20	0.147	0.147	NUM
dpc-2053	70	21	1.047	1.047	NUM
dpc-2053	70	22	sex	sex	NOUN
dpc-2053	70	23	:	:	PUNCT
dpc-2053	70	24	m	m	PROPN
dpc-2053	70	25	–	–	PUNCT
dpc-2053	70	26	f	f	PROPN
dpc-2053	70	27	0.8918	0.8918	NUM
dpc-2053	70	28	1.0390	1.0390	NUM
dpc-2053	70	29	0.858	0.858	NUM
dpc-2053	70	30	0.391	0.391	NUM
dpc-2053	70	31	2.439	2.439	NUM
dpc-2053	70	32	bmi	bmi	NOUN
dpc-2053	70	33	=	=	PUNCT
dpc-2053	70	34	body	body	NOUN
dpc-2053	70	35	mass	mass	PROPN
dpc-2053	70	36	index	index	NOUN
dpc-2053	70	37	;	;	PUNCT
dpc-2053	70	38	f	f	PROPN
dpc-2053	70	39	=	=	NOUN
dpc-2053	70	40	female	female	NOUN
dpc-2053	70	41	;	;	PUNCT
dpc-2053	70	42	m	m	VERB
dpc-2053	70	43	=	=	NOUN
dpc-2053	70	44	male	male	NOUN
dpc-2053	70	45	;	;	PUNCT
dpc-2053	70	46	se	se	X
dpc-2053	70	47	=	=	SYM
dpc-2053	70	48	standard	standard	ADJ
dpc-2053	70	49	error	error	NOUN
dpc-2053	70	50	.	.	PUNCT
dpc-2053	70	51	aestimates	aestimates	PROPN
dpc-2053	70	52	represent	represent	VERB
dpc-2053	70	53	the	the	DET
dpc-2053	70	54	log	log	NOUN
dpc-2053	70	55	odds	odd	NOUN
dpc-2053	70	56	of	of	ADP
dpc-2053	70	57	“	"	PUNCT
dpc-2053	70	58	outcome	outcome	NOUN
dpc-2053	70	59	=	=	PUNCT
dpc-2053	70	60	yes	yes	INTJ
dpc-2053	70	61	”	"	PUNCT
dpc-2053	70	62	versus	versus	ADP
dpc-2053	70	63	 	 	SPACE
dpc-2053	70	64	“	"	PUNCT
dpc-2053	70	65	outcome	outcome	NOUN
dpc-2053	70	66	=	=	PUNCT
dpc-2053	70	67	no	no	NOUN
dpc-2053	70	68	”	"	PUNCT
dpc-2053	70	69	4	4	NUM
dpc-2053	70	70	original	original	ADJ
dpc-2053	70	71	article	article	NOUN
dpc-2053	70	72	|	|	ADV
dpc-2053	70	73	dermatol	dermatol	ADJ
dpc-2053	70	74	pract	pract	NOUN
dpc-2053	70	75	concept	concept	NOUN
dpc-2053	70	76	.	.	PUNCT
dpc-2053	71	1	2022;12(4):e2022148	2022;12(4):e2022148	NUM
dpc-2053	71	2	for	for	ADP
dpc-2053	71	3	patients	patient	NOUN
dpc-2053	71	4	affected	affect	VERB
dpc-2053	71	5	by	by	ADP
dpc-2053	71	6	asthma	asthma	NOUN
dpc-2053	71	7	the	the	DET
dpc-2053	71	8	recommended	recommend	VERB
dpc-2053	71	9	dose	dose	NOUN
dpc-2053	71	10	of	of	ADP
dpc-2053	71	11	omalizumab	omalizumab	NOUN
dpc-2053	71	12	changes	change	NOUN
dpc-2053	71	13	according	accord	VERB
dpc-2053	71	14	to	to	ADP
dpc-2053	71	15	the	the	DET
dpc-2053	71	16	body	body	NOUN
dpc-2053	71	17	weight	weight	NOUN
dpc-2053	71	18	of	of	ADP
dpc-2053	71	19	the	the	DET
dpc-2053	71	20	patient	patient	NOUN
dpc-2053	71	21	,	,	PUNCT
dpc-2053	71	22	a	a	DET
dpc-2053	71	23	fixed	fix	VERB
dpc-2053	71	24	dose	dose	NOUN
dpc-2053	71	25	regimen	regimen	NOUN
dpc-2053	71	26	is	be	AUX
dpc-2053	71	27	recommended	recommend	VERB
dpc-2053	71	28	for	for	ADP
dpc-2053	71	29	csu	csu	PROPN
dpc-2053	71	30	regardless	regardless	ADV
dpc-2053	71	31	of	of	ADP
dpc-2053	71	32	the	the	DET
dpc-2053	71	33	body	body	NOUN
dpc-2053	71	34	weight	weight	NOUN
dpc-2053	71	35	and	and	CCONJ
dpc-2053	71	36	total	total	ADJ
dpc-2053	71	37	ige	ige	PROPN
dpc-2053	71	38	levels	level	NOUN
dpc-2053	71	39	.	.	PUNCT
dpc-2053	72	1	in	in	ADP
dpc-2053	72	2	the	the	DET
dpc-2053	72	3	recent	recent	ADJ
dpc-2053	72	4	years	year	NOUN
dpc-2053	72	5	,	,	PUNCT
dpc-2053	72	6	there	there	PRON
dpc-2053	72	7	have	have	AUX
dpc-2053	72	8	been	be	AUX
dpc-2053	72	9	several	several	ADJ
dpc-2053	72	10	studies	study	NOUN
dpc-2053	72	11	on	on	ADP
dpc-2053	72	12	updosing	updose	VERB
dpc-2053	72	13	of	of	ADP
dpc-2053	72	14	the	the	DET
dpc-2053	72	15	drug	drug	NOUN
dpc-2053	72	16	,	,	PUNCT
dpc-2053	72	17	suggesting	suggest	VERB
dpc-2053	72	18	that	that	SCONJ
dpc-2053	72	19	the	the	DET
dpc-2053	72	20	individualized	individualized	ADJ
dpc-2053	72	21	approach	approach	NOUN
dpc-2053	72	22	for	for	ADP
dpc-2053	72	23	urticaria	urticaria	ADJ
dpc-2053	72	24	treatment	treatment	NOUN
dpc-2053	72	25	with	with	ADP
dpc-2053	72	26	omalizumab	omalizumab	NOUN
dpc-2053	72	27	is	be	AUX
dpc-2053	72	28	useful	useful	ADJ
dpc-2053	72	29	[	[	X
dpc-2053	72	30	16	16	NUM
dpc-2053	72	31	]	]	PUNCT
dpc-2053	72	32	.	.	PUNCT
dpc-2053	73	1	patients	patient	NOUN
dpc-2053	73	2	with	with	ADP
dpc-2053	73	3	a	a	DET
dpc-2053	73	4	higher	high	ADJ
dpc-2053	73	5	bmi	bmi	NOUN
dpc-2053	73	6	have	have	AUX
dpc-2053	73	7	been	be	AUX
dpc-2053	73	8	found	find	VERB
dpc-2053	73	9	to	to	PART
dpc-2053	73	10	require	require	VERB
dpc-2053	73	11	higher	high	ADJ
dpc-2053	73	12	doses	dose	NOUN
dpc-2053	73	13	to	to	PART
dpc-2053	73	14	control	control	VERB
dpc-2053	73	15	the	the	DET
dpc-2053	73	16	disease	disease	NOUN
dpc-2053	73	17	[	[	X
dpc-2053	73	18	17	17	NUM
dpc-2053	73	19	]	]	PUNCT
dpc-2053	73	20	.	.	PUNCT
dpc-2053	74	1	a	a	DET
dpc-2053	74	2	step	step	NOUN
dpc-2053	74	3	-	-	PUNCT
dpc-2053	74	4	wise	wise	ADJ
dpc-2053	74	5	approach	approach	NOUN
dpc-2053	74	6	starting	start	VERB
dpc-2053	74	7	from	from	ADP
dpc-2053	74	8	450	450	NUM
dpc-2053	74	9	mg	mg	NOUN
dpc-2053	74	10	and	and	CCONJ
dpc-2053	74	11	then	then	ADV
dpc-2053	74	12	updosing	updose	VERB
dpc-2053	74	13	to	to	ADP
dpc-2053	74	14	600	600	NUM
dpc-2053	74	15	mg	mg	NOUN
dpc-2053	74	16	has	have	AUX
dpc-2053	74	17	been	be	AUX
dpc-2053	74	18	proposed	propose	VERB
dpc-2053	74	19	if	if	SCONJ
dpc-2053	74	20	there	there	PRON
dpc-2053	74	21	is	be	VERB
dpc-2053	74	22	no	no	DET
dpc-2053	74	23	response	response	NOUN
dpc-2053	74	24	after	after	ADP
dpc-2053	74	25	3	3	NUM
dpc-2053	74	26	months	month	NOUN
dpc-2053	74	27	of	of	ADP
dpc-2053	74	28	treatment	treatment	NOUN
dpc-2053	74	29	in	in	ADP
dpc-2053	74	30	csu	csu	PROPN
dpc-2053	74	31	patients	patient	NOUN
dpc-2053	75	1	[	[	X
dpc-2053	75	2	17	17	NUM
dpc-2053	75	3	]	]	PUNCT
dpc-2053	75	4	.	.	PUNCT
dpc-2053	76	1	furthermore	furthermore	ADV
dpc-2053	76	2	intervention	intervention	NOUN
dpc-2053	76	3	on	on	ADP
dpc-2053	76	4	lifestyle	lifestyle	NOUN
dpc-2053	76	5	through	through	ADP
dpc-2053	76	6	a	a	DET
dpc-2053	76	7	combination	combination	NOUN
dpc-2053	76	8	of	of	ADP
dpc-2053	76	9	dietary	dietary	ADJ
dpc-2053	76	10	changing	change	VERB
dpc-2053	76	11	and	and	CCONJ
dpc-2053	76	12	physical	physical	ADJ
dpc-2053	76	13	activity	activity	NOUN
dpc-2053	76	14	should	should	AUX
dpc-2053	76	15	be	be	AUX
dpc-2053	76	16	recommended	recommend	VERB
dpc-2053	76	17	in	in	ADP
dpc-2053	76	18	patients	patient	NOUN
dpc-2053	76	19	with	with	ADP
dpc-2053	76	20	high	high	ADJ
dpc-2053	76	21	bmi	bmi	NOUN
dpc-2053	76	22	.	.	PUNCT
dpc-2053	77	1	total	total	ADJ
dpc-2053	77	2	ige	ige	PROPN
dpc-2053	77	3	serum	serum	PROPN
dpc-2053	77	4	level	level	NOUN
dpc-2053	77	5	do	do	AUX
dpc-2053	77	6	not	not	PART
dpc-2053	77	7	justify	justify	VERB
dpc-2053	77	8	an	an	DET
dpc-2053	77	9	omalizumab	omalizumab	NOUN
dpc-2053	77	10	dose	dose	NOUN
dpc-2053	77	11	changing	change	VERB
dpc-2053	77	12	however	however	ADV
dpc-2053	77	13	,	,	PUNCT
dpc-2053	77	14	it	it	PRON
dpc-2053	77	15	is	be	AUX
dpc-2053	77	16	a	a	DET
dpc-2053	77	17	reliable	reliable	ADJ
dpc-2053	77	18	biomarker	biomarker	NOUN
dpc-2053	77	19	predicting	predict	VERB
dpc-2053	77	20	response	response	NOUN
dpc-2053	77	21	to	to	ADP
dpc-2053	77	22	omalizumab	omalizumab	NOUN
dpc-2053	77	23	in	in	ADP
dpc-2053	77	24	csu	csu	PROPN
dpc-2053	77	25	since	since	SCONJ
dpc-2053	77	26	levels	level	NOUN
dpc-2053	77	27	are	be	AUX
dpc-2053	77	28	significantly	significantly	ADV
dpc-2053	77	29	higher	high	ADJ
dpc-2053	77	30	in	in	ADP
dpc-2053	77	31	responder	responder	NOUN
dpc-2053	77	32	than	than	ADP
dpc-2053	77	33	non	non	ADJ
dpc-2053	77	34	-	-	ADJ
dpc-2053	77	35	responder	responder	ADJ
dpc-2053	77	36	patients	patient	NOUN
dpc-2053	77	37	[	[	X
dpc-2053	77	38	18	18	NUM
dpc-2053	77	39	]	]	PUNCT
dpc-2053	77	40	.	.	PUNCT
dpc-2053	78	1	the	the	DET
dpc-2053	78	2	main	main	ADJ
dpc-2053	78	3	limitation	limitation	NOUN
dpc-2053	78	4	of	of	ADP
dpc-2053	78	5	our	our	PRON
dpc-2053	78	6	study	study	NOUN
dpc-2053	78	7	is	be	AUX
dpc-2053	78	8	the	the	DET
dpc-2053	78	9	small	small	ADJ
dpc-2053	78	10	number	number	NOUN
dpc-2053	78	11	of	of	ADP
dpc-2053	78	12	patients	patient	NOUN
dpc-2053	78	13	included	include	VERB
dpc-2053	78	14	.	.	PUNCT
dpc-2053	79	1	furthermore	furthermore	ADV
dpc-2053	79	2	,	,	PUNCT
dpc-2053	79	3	all	all	DET
dpc-2053	79	4	patients	patient	NOUN
dpc-2053	79	5	had	have	VERB
dpc-2053	79	6	a	a	DET
dpc-2053	79	7	high	high	ADJ
dpc-2053	79	8	uas	uas	NOUN
dpc-2053	79	9	and	and	CCONJ
dpc-2053	79	10	some	some	DET
dpc-2053	79	11	patients	patient	NOUN
dpc-2053	79	12	continued	continue	VERB
dpc-2053	79	13	antihistamines	antihistamine	NOUN
dpc-2053	79	14	and	and	CCONJ
dpc-2053	79	15	corticosteroids	corticosteroid	NOUN
dpc-2053	79	16	during	during	ADP
dpc-2053	79	17	omalizumab	omalizumab	NOUN
dpc-2053	79	18	.	.	PUNCT
dpc-2053	80	1	we	we	PRON
dpc-2053	80	2	know	know	VERB
dpc-2053	80	3	that	that	SCONJ
dpc-2053	80	4	these	these	PRON
dpc-2053	80	5	may	may	AUX
dpc-2053	80	6	be	be	AUX
dpc-2053	80	7	confounding	confound	VERB
dpc-2053	80	8	factors	factor	NOUN
dpc-2053	80	9	that	that	PRON
dpc-2053	80	10	may	may	AUX
dpc-2053	80	11	have	have	AUX
dpc-2053	80	12	influenced	influence	VERB
dpc-2053	80	13	the	the	DET
dpc-2053	80	14	outcome	outcome	NOUN
dpc-2053	80	15	.	.	PUNCT
dpc-2053	81	1	in	in	ADP
dpc-2053	81	2	conclusion	conclusion	NOUN
dpc-2053	81	3	,	,	PUNCT
dpc-2053	81	4	in	in	ADP
dpc-2053	81	5	this	this	DET
dpc-2053	81	6	study	study	NOUN
dpc-2053	81	7	we	we	PRON
dpc-2053	81	8	identified	identify	VERB
dpc-2053	81	9	bmi	bmi	NOUN
dpc-2053	81	10	as	as	ADP
dpc-2053	81	11	a	a	DET
dpc-2053	81	12	critical	critical	ADJ
dpc-2053	81	13	biological	biological	ADJ
dpc-2053	81	14	factor	factor	NOUN
dpc-2053	81	15	that	that	PRON
dpc-2053	81	16	significantly	significantly	ADV
dpc-2053	81	17	impacts	impact	VERB
dpc-2053	81	18	the	the	DET
dpc-2053	81	19	outcomes	outcome	NOUN
dpc-2053	81	20	of	of	ADP
dpc-2053	81	21	omalizumab	omalizumab	NOUN
dpc-2053	81	22	treatment	treatment	NOUN
dpc-2053	81	23	.	.	PUNCT
dpc-2053	82	1	our	our	PRON
dpc-2053	82	2	findings	finding	NOUN
dpc-2053	82	3	also	also	ADV
dpc-2053	82	4	suggest	suggest	VERB
dpc-2053	82	5	a	a	DET
dpc-2053	82	6	potential	potential	ADJ
dpc-2053	82	7	use	use	NOUN
dpc-2053	82	8	of	of	ADP
dpc-2053	82	9	bmi	bmi	NOUN
dpc-2053	82	10	as	as	ADP
dpc-2053	82	11	a	a	DET
dpc-2053	82	12	predictive	predictive	ADJ
dpc-2053	82	13	biomarker	biomarker	NOUN
dpc-2053	82	14	for	for	ADP
dpc-2053	82	15	omalizumab	omalizumab	NOUN
dpc-2053	82	16	treatment	treatment	NOUN
dpc-2053	82	17	.	.	PUNCT
dpc-2053	83	1	an	an	DET
dpc-2053	83	2	up	up	ADV
dpc-2053	83	3	-	-	PUNCT
dpc-2053	83	4	dosing	dosing	NOUN
dpc-2053	83	5	of	of	ADP
dpc-2053	83	6	omalizumab	omalizumab	NOUN
dpc-2053	83	7	may	may	AUX
dpc-2053	83	8	be	be	AUX
dpc-2053	83	9	proposed	propose	VERB
dpc-2053	83	10	in	in	ADP
dpc-2053	83	11	patients	patient	NOUN
dpc-2053	83	12	with	with	ADP
dpc-2053	83	13	high	high	ADJ
dpc-2053	83	14	bmi	bmi	NOUN
dpc-2053	83	15	to	to	PART
dpc-2053	83	16	achieve	achieve	VERB
dpc-2053	83	17	a	a	DET
dpc-2053	83	18	better	well	ADJ
dpc-2053	83	19	control	control	NOUN
dpc-2053	83	20	of	of	ADP
dpc-2053	83	21	the	the	DET
dpc-2053	83	22	disease	disease	NOUN
dpc-2053	83	23	.	.	PUNCT
dpc-2053	84	1	references	reference	NOUN
dpc-2053	84	2	1	1	NUM
dpc-2053	84	3	.	.	PUNCT
dpc-2053	84	4	maurer	maurer	PROPN
dpc-2053	84	5	m	m	PROPN
dpc-2053	84	6	,	,	PUNCT
dpc-2053	84	7	weller	weller	PROPN
dpc-2053	84	8	k	k	PROPN
dpc-2053	84	9	,	,	PUNCT
dpc-2053	84	10	gime	gime	VERB
dpc-2053	84	11	a	a	PRON
dpc-2053	84	12	,	,	PUNCT
dpc-2053	84	13	et	et	PROPN
dpc-2053	84	14	al	al	PROPN
dpc-2053	84	15	.	.	PUNCT
dpc-2053	85	1	unmet	unmet	PROPN
dpc-2053	85	2	clinical	clinical	ADJ
dpc-2053	85	3	needs	need	NOUN
dpc-2053	85	4	in	in	ADP
dpc-2053	85	5	chronic	chronic	ADJ
dpc-2053	85	6	spontaneous	spontaneous	ADJ
dpc-2053	85	7	urticaria	urticaria	NOUN
dpc-2053	85	8	.	.	PUNCT
dpc-2053	86	1	a	a	DET
dpc-2053	86	2	ga²len	ga²len	PROPN
dpc-2053	86	3	task	task	NOUN
dpc-2053	86	4	force	force	NOUN
dpc-2053	86	5	report	report	NOUN
dpc-2053	86	6	.	.	PUNCT
dpc-2053	87	1	allergy	allergy	NOUN
dpc-2053	87	2	.	.	PUNCT
dpc-2053	88	1	2011;66(3):317	2011;66(3):317	NUM
dpc-2053	88	2	-	-	SYM
dpc-2053	88	3	330	330	NUM
dpc-2053	88	4	.	.	PUNCT
dpc-2053	89	1	doi	doi	NOUN
dpc-2053	89	2	:	:	PUNCT
dpc-2053	89	3	10.1111	10.1111	NUM
dpc-2053	89	4	/	/	SYM
dpc-2053	89	5	j.1398	j.1398	PROPN
dpc-2053	89	6	-	-	PUNCT
dpc-2053	89	7	9995.2010.02496.x	9995.2010.02496.x	NUM
dpc-2053	89	8	.	.	PUNCT
dpc-2053	90	1	pmid	pmid	NOUN
dpc-2053	90	2	:	:	PUNCT
dpc-2053	90	3	21083565	21083565	NUM
dpc-2053	90	4	.	.	PUNCT
dpc-2053	91	1	2	2	X
dpc-2053	91	2	.	.	X
dpc-2053	91	3	nettis	nettis	PROPN
dpc-2053	91	4	e	e	PROPN
dpc-2053	91	5	,	,	PUNCT
dpc-2053	91	6	foti	foti	PROPN
dpc-2053	91	7	c	c	PROPN
dpc-2053	91	8	,	,	PUNCT
dpc-2053	91	9	ambrifi	ambrifi	PROPN
dpc-2053	91	10	m	m	PROPN
dpc-2053	91	11	,	,	PUNCT
dpc-2053	91	12	et	et	PROPN
dpc-2053	91	13	al	al	PROPN
dpc-2053	91	14	.	.	PUNCT
dpc-2053	92	1	urticaria	urticaria	PROPN
dpc-2053	92	2	:	:	PUNCT
dpc-2053	92	3	recommendations	recommendation	NOUN
dpc-2053	92	4	from	from	ADP
dpc-2053	92	5	the	the	DET
dpc-2053	92	6	italian	italian	ADJ
dpc-2053	92	7	society	society	NOUN
dpc-2053	92	8	of	of	ADP
dpc-2053	92	9	allergology	allergology	NOUN
dpc-2053	92	10	,	,	PUNCT
dpc-2053	92	11	asthma	asthma	NOUN
dpc-2053	92	12	and	and	CCONJ
dpc-2053	92	13	clinical	clinical	ADJ
dpc-2053	92	14	immunology	immunology	NOUN
dpc-2053	92	15	and	and	CCONJ
dpc-2053	92	16	the	the	DET
dpc-2053	92	17	italian	italian	ADJ
dpc-2053	92	18	society	society	NOUN
dpc-2053	92	19	of	of	ADP
dpc-2053	92	20	allergological	allergological	ADJ
dpc-2053	92	21	,	,	PUNCT
dpc-2053	92	22	occupational	occupational	ADJ
dpc-2053	92	23	and	and	CCONJ
dpc-2053	92	24	environmental	environmental	ADJ
dpc-2053	92	25	dermatology	dermatology	NOUN
dpc-2053	92	26	.	.	PUNCT
dpc-2053	93	1	clin	clin	PROPN
dpc-2053	93	2	mol	mol	PROPN
dpc-2053	93	3	allergy	allergy	PROPN
dpc-2053	93	4	.	.	PUNCT
dpc-2053	94	1	2020;18:8	2020;18:8	X
dpc-2053	94	2	.	.	PUNCT
dpc-2053	94	3	doi	doi	NOUN
dpc-2053	94	4	:	:	PUNCT
dpc-2053	94	5	10.1186	10.1186	NUM
dpc-2053	94	6	/	/	SYM
dpc-2053	94	7	s12948	s12948	PROPN
dpc-2053	94	8	-	-	PUNCT
dpc-2053	94	9	020	020	NUM
dpc-2053	94	10	-	-	PUNCT
dpc-2053	94	11	00123	00123	NUM
dpc-2053	94	12	-	-	SYM
dpc-2053	94	13	8	8	NUM
dpc-2053	94	14	.	.	PUNCT
dpc-2053	95	1	pmid	pmid	NOUN
dpc-2053	95	2	:	:	PUNCT
dpc-2053	95	3	32390768;pmcid	32390768;pmcid	NUM
dpc-2053	95	4	:	:	PUNCT
dpc-2053	95	5	pmc7201804	pmc7201804	NOUN
dpc-2053	95	6	.	.	PUNCT
dpc-2053	96	1	3	3	X
dpc-2053	96	2	.	.	X
dpc-2053	96	3	zuberbier	zuberbier	PROPN
dpc-2053	96	4	t	t	PROPN
dpc-2053	96	5	,	,	PUNCT
dpc-2053	96	6	abdul	abdul	PROPN
dpc-2053	96	7	latiff	latiff	PROPN
dpc-2053	96	8	ah	ah	INTJ
dpc-2053	96	9	,	,	PUNCT
dpc-2053	96	10	abuzakouk	abuzakouk	PROPN
dpc-2053	96	11	m	m	PROPN
dpc-2053	96	12	,	,	PUNCT
dpc-2053	96	13	et	et	PROPN
dpc-2053	96	14	al	al	PROPN
dpc-2053	96	15	.	.	PUNCT
dpc-2053	97	1	the	the	DET
dpc-2053	97	2	international	international	PROPN
dpc-2053	97	3	eaaci	eaaci	PROPN
dpc-2053	97	4	/	/	SYM
dpc-2053	97	5	ga²len	ga²len	PROPN
dpc-2053	97	6	/	/	SYM
dpc-2053	97	7	euroguiderm	euroguiderm	NOUN
dpc-2053	97	8	/	/	SYM
dpc-2053	97	9	apaaaci	apaaaci	NOUN
dpc-2053	97	10	guideline	guideline	NOUN
dpc-2053	97	11	for	for	ADP
dpc-2053	97	12	the	the	DET
dpc-2053	97	13	definition	definition	NOUN
dpc-2053	97	14	,	,	PUNCT
dpc-2053	97	15	classification	classification	NOUN
dpc-2053	97	16	,	,	PUNCT
dpc-2053	97	17	diagnosis	diagnosis	NOUN
dpc-2053	97	18	,	,	PUNCT
dpc-2053	97	19	and	and	CCONJ
dpc-2053	97	20	management	management	NOUN
dpc-2053	97	21	of	of	ADP
dpc-2053	97	22	urticaria	urticaria	NOUN
dpc-2053	97	23	.	.	PUNCT
dpc-2053	98	1	allergy	allergy	NOUN
dpc-2053	98	2	.	.	PUNCT
dpc-2053	99	1	2022;77(3):734	2022;77(3):734	NUM
dpc-2053	99	2	-	-	PUNCT
dpc-2053	99	3	766	766	NUM
dpc-2053	99	4	.	.	PUNCT
dpc-2053	100	1	doi	doi	NOUN
dpc-2053	100	2	:	:	PUNCT
dpc-2053	100	3	10.1111	10.1111	NUM
dpc-2053	100	4	/	/	SYM
dpc-2053	100	5	all.15090	all.15090	NOUN
dpc-2053	100	6	.	.	PUNCT
dpc-2053	101	1	pmid	pmid	NOUN
dpc-2053	101	2	:	:	PUNCT
dpc-2053	101	3	34536239	34536239	NUM
dpc-2053	101	4	.	.	PUNCT
dpc-2053	102	1	4	4	X
dpc-2053	102	2	.	.	X
dpc-2053	102	3	antia	antia	PROPN
dpc-2053	102	4	c	c	PROPN
dpc-2053	102	5	,	,	PUNCT
dpc-2053	102	6	baquerizo	baquerizo	PROPN
dpc-2053	102	7	k	k	PROPN
dpc-2053	102	8	,	,	PUNCT
dpc-2053	102	9	korman	korman	PROPN
dpc-2053	102	10	a	a	PROPN
dpc-2053	102	11	,	,	PUNCT
dpc-2053	102	12	bernstein	bernstein	PROPN
dpc-2053	102	13	ja	ja	PROPN
dpc-2053	102	14	,	,	PUNCT
dpc-2053	102	15	alikhan	alikhan	ADP
dpc-2053	102	16	a.	a.	NOUN
dpc-2053	102	17	urticaria	urticaria	PROPN
dpc-2053	102	18	:	:	PUNCT
dpc-2053	102	19	a	a	DET
dpc-2053	102	20	comprehensive	comprehensive	ADJ
dpc-2053	102	21	review	review	NOUN
dpc-2053	102	22	:	:	PUNCT
dpc-2053	102	23	epidemiology	epidemiology	NOUN
dpc-2053	102	24	,	,	PUNCT
dpc-2053	102	25	diagnosis	diagnosis	NOUN
dpc-2053	102	26	,	,	PUNCT
dpc-2053	102	27	and	and	CCONJ
dpc-2053	102	28	work	work	NOUN
dpc-2053	102	29	-	-	PUNCT
dpc-2053	102	30	up	up	NOUN
dpc-2053	102	31	.	.	PUNCT
dpc-2053	103	1	j	j	PROPN
dpc-2053	103	2	am	be	AUX
dpc-2053	103	3	acad	acad	PROPN
dpc-2053	103	4	dermatol.2018;79(4):599	dermatol.2018;79(4):599	PROPN
dpc-2053	103	5	-	-	PUNCT
dpc-2053	103	6	614	614	NUM
dpc-2053	103	7	.	.	PUNCT
dpc-2053	104	1	doi	doi	NOUN
dpc-2053	104	2	:	:	PUNCT
dpc-2053	104	3	10.1016	10.1016	NUM
dpc-2053	104	4	/	/	SYM
dpc-2053	104	5	j.jaad.2018.01.020	j.jaad.2018.01.020	PROPN
dpc-2053	104	6	.	.	PUNCT
dpc-2053	105	1	pmid	pmid	NOUN
dpc-2053	105	2	:	:	PUNCT
dpc-2053	105	3	30241623	30241623	NUM
dpc-2053	105	4	.	.	PUNCT
dpc-2053	106	1	5	5	X
dpc-2053	106	2	.	.	X
dpc-2053	106	3	pelaia	pelaia	PROPN
dpc-2053	106	4	c	c	PROPN
dpc-2053	106	5	,	,	PUNCT
dpc-2053	106	6	calabrese	calabrese	PROPN
dpc-2053	106	7	c	c	NOUN
dpc-2053	106	8	,	,	PUNCT
dpc-2053	106	9	terracciano	terracciano	ADJ
dpc-2053	106	10	r	r	NOUN
dpc-2053	106	11	,	,	PUNCT
dpc-2053	106	12	de	de	X
dpc-2053	106	13	blasio	blasio	NOUN
dpc-2053	106	14	f	f	NOUN
dpc-2053	106	15	,	,	PUNCT
dpc-2053	106	16	vatrella	vatrella	PROPN
dpc-2053	106	17	a	a	NOUN
dpc-2053	106	18	,	,	PUNCT
dpc-2053	106	19	pelaia	pelaia	PROPN
dpc-2053	106	20	g.	g.	PROPN
dpc-2053	106	21	omalizumab	omalizumab	PROPN
dpc-2053	106	22	,	,	PUNCT
dpc-2053	106	23	the	the	DET
dpc-2053	106	24	first	first	ADJ
dpc-2053	106	25	available	available	ADJ
dpc-2053	106	26	antibody	antibody	NOUN
dpc-2053	106	27	for	for	ADP
dpc-2053	106	28	biological	biological	ADJ
dpc-2053	106	29	treatment	treatment	NOUN
dpc-2053	106	30	of	of	ADP
dpc-2053	106	31	severe	severe	ADJ
dpc-2053	106	32	asthma	asthma	NOUN
dpc-2053	106	33	:	:	PUNCT
dpc-2053	106	34	more	more	ADJ
dpc-2053	106	35	than	than	ADP
dpc-2053	106	36	a	a	PRON
dpc-2053	106	37	decade	decade	NOUN
dpc-2053	106	38	of	of	ADP
dpc-2053	106	39	pathogenesis	pathogenesis	NOUN
dpc-2053	106	40	[	[	X
dpc-2053	106	41	3	3	NUM
dpc-2053	106	42	]	]	PUNCT
dpc-2053	106	43	.	.	PUNCT
dpc-2053	107	1	patients	patient	NOUN
dpc-2053	107	2	aged	age	VERB
dpc-2053	107	3	from	from	ADP
dpc-2053	107	4	21	21	NUM
dpc-2053	107	5	to	to	PART
dpc-2053	107	6	81	81	NUM
dpc-2053	107	7	years	year	NOUN
dpc-2053	107	8	have	have	AUX
dpc-2053	107	9	been	be	AUX
dpc-2053	107	10	treated	treat	VERB
dpc-2053	107	11	,	,	PUNCT
dpc-2053	107	12	showing	show	VERB
dpc-2053	107	13	omalizumab	omalizumab	NOUN
dpc-2053	107	14	safety	safety	NOUN
dpc-2053	107	15	in	in	ADP
dpc-2053	107	16	all	all	DET
dpc-2053	107	17	age	age	NOUN
dpc-2053	107	18	groups	group	NOUN
dpc-2053	107	19	,	,	PUNCT
dpc-2053	107	20	even	even	ADV
dpc-2053	107	21	in	in	ADP
dpc-2053	107	22	the	the	DET
dpc-2053	107	23	elderly	elderly	ADJ
dpc-2053	107	24	patients	patient	NOUN
dpc-2053	107	25	which	which	PRON
dpc-2053	107	26	may	may	AUX
dpc-2053	107	27	have	have	VERB
dpc-2053	107	28	comorbidities	comorbiditie	NOUN
dpc-2053	107	29	[	[	X
dpc-2053	107	30	9	9	NUM
dpc-2053	107	31	]	]	PUNCT
dpc-2053	107	32	.	.	PUNCT
dpc-2053	108	1	the	the	DET
dpc-2053	108	2	average	average	ADJ
dpc-2053	108	3	value	value	NOUN
dpc-2053	108	4	of	of	ADP
dpc-2053	108	5	bmi	bmi	NOUN
dpc-2053	108	6	was	be	AUX
dpc-2053	108	7	24.1	24.1	NUM
dpc-2053	108	8	kg	kg	NOUN
dpc-2053	108	9	/	/	SYM
dpc-2053	108	10	m2	m2	PROPN
dpc-2053	108	11	,	,	PUNCT
dpc-2053	108	12	which	which	PRON
dpc-2053	108	13	belongs	belong	VERB
dpc-2053	108	14	to	to	ADP
dpc-2053	108	15	the	the	DET
dpc-2053	108	16	category	category	NOUN
dpc-2053	108	17	of	of	ADP
dpc-2053	108	18	normal	normal	ADJ
dpc-2053	108	19	weight	weight	NOUN
dpc-2053	108	20	but	but	CCONJ
dpc-2053	108	21	with	with	ADP
dpc-2053	108	22	a	a	DET
dpc-2053	108	23	tendency	tendency	NOUN
dpc-2053	108	24	to	to	PART
dpc-2053	108	25	overweight	overweight	VERB
dpc-2053	108	26	.	.	PUNCT
dpc-2053	109	1	although	although	SCONJ
dpc-2053	109	2	the	the	DET
dpc-2053	109	3	study	study	NOUN
dpc-2053	109	4	population	population	NOUN
dpc-2053	109	5	is	be	AUX
dpc-2053	109	6	not	not	PART
dpc-2053	109	7	large	large	ADJ
dpc-2053	109	8	,	,	PUNCT
dpc-2053	109	9	the	the	DET
dpc-2053	109	10	distribution	distribution	NOUN
dpc-2053	109	11	of	of	ADP
dpc-2053	109	12	bmi	bmi	NOUN
dpc-2053	109	13	categories	category	NOUN
dpc-2053	109	14	was	be	AUX
dpc-2053	109	15	overlapping	overlap	VERB
dpc-2053	109	16	to	to	ADP
dpc-2053	109	17	the	the	DET
dpc-2053	109	18	percentage	percentage	NOUN
dpc-2053	109	19	obtained	obtain	VERB
dpc-2053	109	20	by	by	ADP
dpc-2053	109	21	2016	2016	NUM
dpc-2053	109	22	istat	istat	X
dpc-2053	109	23	on	on	ADP
dpc-2053	109	24	the	the	DET
dpc-2053	109	25	entire	entire	ADJ
dpc-2053	109	26	italian	italian	ADJ
dpc-2053	109	27	population	population	NOUN
dpc-2053	109	28	.	.	PUNCT
dpc-2053	110	1	the	the	DET
dpc-2053	110	2	most	most	ADV
dpc-2053	110	3	common	common	ADJ
dpc-2053	110	4	diseases	disease	NOUN
dpc-2053	110	5	associated	associate	VERB
dpc-2053	110	6	with	with	ADP
dpc-2053	110	7	csu	csu	PROPN
dpc-2053	110	8	were	be	AUX
dpc-2053	110	9	hypothyroidism	hypothyroidism	NOUN
dpc-2053	110	10	,	,	PUNCT
dpc-2053	110	11	hypertension	hypertension	NOUN
dpc-2053	110	12	,	,	PUNCT
dpc-2053	110	13	allergic	allergic	ADJ
dpc-2053	110	14	rhinitis	rhinitis	NOUN
dpc-2053	110	15	,	,	PUNCT
dpc-2053	110	16	nickel	nickel	NOUN
dpc-2053	110	17	and	and	CCONJ
dpc-2053	110	18	grass	grass	NOUN
dpc-2053	110	19	allergy	allergy	NOUN
dpc-2053	110	20	and	and	CCONJ
dpc-2053	110	21	atopic	atopic	NOUN
dpc-2053	110	22	dermatitis	dermatitis	NOUN
dpc-2053	110	23	.	.	PUNCT
dpc-2053	111	1	several	several	ADJ
dpc-2053	111	2	patients	patient	NOUN
dpc-2053	111	3	included	include	VERB
dpc-2053	111	4	in	in	ADP
dpc-2053	111	5	our	our	PRON
dpc-2053	111	6	case	case	NOUN
dpc-2053	111	7	series	series	NOUN
dpc-2053	111	8	were	be	AUX
dpc-2053	111	9	also	also	ADV
dpc-2053	111	10	affected	affect	VERB
dpc-2053	111	11	by	by	ADP
dpc-2053	111	12	atopic	atopic	NOUN
dpc-2053	111	13	dermatitis	dermatitis	NOUN
dpc-2053	111	14	,	,	PUNCT
dpc-2053	111	15	vitiligo	vitiligo	NOUN
dpc-2053	111	16	,	,	PUNCT
dpc-2053	111	17	psoriasis	psoriasis	NOUN
dpc-2053	111	18	,	,	PUNCT
dpc-2053	111	19	alopecia	alopecia	NOUN
dpc-2053	111	20	,	,	PUNCT
dpc-2053	111	21	sle	sle	PROPN
dpc-2053	111	22	,	,	PUNCT
dpc-2053	111	23	scleroderma	scleroderma	NOUN
dpc-2053	111	24	,	,	PUNCT
dpc-2053	111	25	spondylarthritis	spondylarthritis	PROPN
dpc-2053	111	26	and/or	and/or	CCONJ
dpc-2053	111	27	diabetes	diabetes	NOUN
dpc-2053	111	28	suggesting	suggest	VERB
dpc-2053	111	29	a	a	DET
dpc-2053	111	30	potential	potential	ADJ
dpc-2053	111	31	role	role	NOUN
dpc-2053	111	32	of	of	ADP
dpc-2053	111	33	autoimmunity	autoimmunity	NOUN
dpc-2053	111	34	.	.	PUNCT
dpc-2053	112	1	our	our	PRON
dpc-2053	112	2	patients	patient	NOUN
dpc-2053	112	3	continued	continue	VERB
dpc-2053	112	4	their	their	PRON
dpc-2053	112	5	concomitant	concomitant	ADJ
dpc-2053	112	6	treatments	treatment	NOUN
dpc-2053	112	7	during	during	ADP
dpc-2053	112	8	omalizumab	omalizumab	NOUN
dpc-2053	112	9	cycles	cycle	NOUN
dpc-2053	112	10	,	,	PUNCT
dpc-2053	112	11	including	include	VERB
dpc-2053	112	12	antihistamines	antihistamine	NOUN
dpc-2053	112	13	(	(	PUNCT
dpc-2053	112	14	60	60	NUM
dpc-2053	112	15	%	%	NOUN
dpc-2053	112	16	of	of	ADP
dpc-2053	112	17	patients	patient	NOUN
dpc-2053	112	18	)	)	PUNCT
dpc-2053	112	19	and	and	CCONJ
dpc-2053	112	20	low	low	ADV
dpc-2053	112	21	-	-	PUNCT
dpc-2053	112	22	dose	dose	NOUN
dpc-2053	112	23	oral	oral	ADJ
dpc-2053	112	24	corticosteroids	corticosteroid	NOUN
dpc-2053	112	25	(	(	PUNCT
dpc-2053	112	26	55	55	NUM
dpc-2053	112	27	%	%	NOUN
dpc-2053	112	28	of	of	ADP
dpc-2053	112	29	patients	patient	NOUN
dpc-2053	112	30	)	)	PUNCT
dpc-2053	112	31	intake	intake	NOUN
dpc-2053	112	32	.	.	PUNCT
dpc-2053	113	1	in	in	ADP
dpc-2053	113	2	addition	addition	NOUN
dpc-2053	113	3	,	,	PUNCT
dpc-2053	113	4	15	15	NUM
dpc-2053	113	5	%	%	NOUN
dpc-2053	113	6	of	of	ADP
dpc-2053	113	7	patients	patient	NOUN
dpc-2053	113	8	continued	continue	VERB
dpc-2053	113	9	to	to	PART
dpc-2053	113	10	follow	follow	VERB
dpc-2053	113	11	a	a	DET
dpc-2053	113	12	histamine	histamine	NOUN
dpc-2053	113	13	-	-	PUNCT
dpc-2053	113	14	free	free	ADJ
dpc-2053	113	15	diet	diet	NOUN
dpc-2053	113	16	and	and	CCONJ
dpc-2053	113	17	12.5	12.5	NUM
dpc-2053	113	18	%	%	NOUN
dpc-2053	113	19	were	be	AUX
dpc-2053	113	20	taking	take	VERB
dpc-2053	113	21	nicotinamide	nicotinamide	NOUN
dpc-2053	113	22	.	.	PUNCT
dpc-2053	114	1	no	no	DET
dpc-2053	114	2	pharmacological	pharmacological	ADJ
dpc-2053	114	3	interactions	interaction	NOUN
dpc-2053	114	4	were	be	AUX
dpc-2053	114	5	observed	observe	VERB
dpc-2053	114	6	,	,	PUNCT
dpc-2053	114	7	confirming	confirm	VERB
dpc-2053	114	8	literature	literature	NOUN
dpc-2053	114	9	data	datum	NOUN
dpc-2053	114	10	[	[	X
dpc-2053	114	11	7,10	7,10	X
dpc-2053	114	12	]	]	PUNCT
dpc-2053	114	13	.	.	PUNCT
dpc-2053	115	1	most	most	ADJ
dpc-2053	115	2	of	of	ADP
dpc-2053	115	3	patients	patient	NOUN
dpc-2053	115	4	(	(	PUNCT
dpc-2053	115	5	57.5	57.5	NUM
dpc-2053	115	6	%	%	NOUN
dpc-2053	115	7	)	)	PUNCT
dpc-2053	115	8	had	have	VERB
dpc-2053	115	9	a	a	DET
dpc-2053	115	10	complete	complete	ADJ
dpc-2053	115	11	response	response	NOUN
dpc-2053	115	12	.	.	PUNCT
dpc-2053	116	1	moreover	moreover	ADV
dpc-2053	116	2	,	,	PUNCT
dpc-2053	116	3	considering	consider	VERB
dpc-2053	116	4	partial	partial	ADJ
dpc-2053	116	5	responses	response	NOUN
dpc-2053	116	6	and	and	CCONJ
dpc-2053	116	7	first	first	ADJ
dpc-2053	116	8	cycle	cycle	NOUN
dpc-2053	116	9	benefits	benefit	NOUN
dpc-2053	116	10	,	,	PUNCT
dpc-2053	116	11	30	30	NUM
dpc-2053	116	12	out	out	ADP
dpc-2053	116	13	of	of	ADP
dpc-2053	116	14	40	40	NUM
dpc-2053	116	15	patients	patient	NOUN
dpc-2053	116	16	(	(	PUNCT
dpc-2053	116	17	75	75	NUM
dpc-2053	116	18	%	%	NOUN
dpc-2053	116	19	)	)	PUNCT
dpc-2053	116	20	had	have	VERB
dpc-2053	116	21	at	at	ADP
dpc-2053	116	22	least	least	ADJ
dpc-2053	116	23	a	a	DET
dpc-2053	116	24	partial	partial	ADJ
dpc-2053	116	25	favorable	favorable	ADJ
dpc-2053	116	26	response	response	NOUN
dpc-2053	116	27	.	.	PUNCT
dpc-2053	117	1	given	give	VERB
dpc-2053	117	2	the	the	DET
dpc-2053	117	3	small	small	ADJ
dpc-2053	117	4	number	number	NOUN
dpc-2053	117	5	of	of	ADP
dpc-2053	117	6	subjects	subject	NOUN
dpc-2053	117	7	recruited	recruit	VERB
dpc-2053	117	8	a	a	DET
dpc-2053	117	9	statistical	statistical	ADJ
dpc-2053	117	10	analysis	analysis	NOUN
dpc-2053	117	11	has	have	AUX
dpc-2053	117	12	not	not	PART
dpc-2053	117	13	been	be	AUX
dpc-2053	117	14	performed	perform	VERB
dpc-2053	117	15	,	,	PUNCT
dpc-2053	117	16	but	but	CCONJ
dpc-2053	117	17	a	a	DET
dpc-2053	117	18	significant	significant	ADJ
dpc-2053	117	19	number	number	NOUN
dpc-2053	117	20	of	of	ADP
dpc-2053	117	21	patients	patient	NOUN
dpc-2053	117	22	with	with	ADP
dpc-2053	117	23	a	a	DET
dpc-2053	117	24	beneficial	beneficial	ADJ
dpc-2053	117	25	effect	effect	NOUN
dpc-2053	117	26	from	from	ADP
dpc-2053	117	27	the	the	DET
dpc-2053	117	28	use	use	NOUN
dpc-2053	117	29	of	of	ADP
dpc-2053	117	30	omalizumab	omalizumab	NOUN
dpc-2053	117	31	has	have	AUX
dpc-2053	117	32	emerged	emerge	VERB
dpc-2053	117	33	.	.	PUNCT
dpc-2053	118	1	concerning	concern	VERB
dpc-2053	118	2	the	the	DET
dpc-2053	118	3	occurrence	occurrence	NOUN
dpc-2053	118	4	of	of	ADP
dpc-2053	118	5	adverse	adverse	ADJ
dpc-2053	118	6	reactions	reaction	NOUN
dpc-2053	118	7	to	to	PART
dpc-2053	118	8	omalizumab	omalizumab	VERB
dpc-2053	118	9	,	,	PUNCT
dpc-2053	118	10	only	only	ADV
dpc-2053	118	11	2	2	NUM
dpc-2053	118	12	cases	case	NOUN
dpc-2053	118	13	out	out	ADP
dpc-2053	118	14	of	of	ADP
dpc-2053	118	15	40	40	NUM
dpc-2053	118	16	(	(	PUNCT
dpc-2053	118	17	5	5	NUM
dpc-2053	118	18	%	%	NOUN
dpc-2053	118	19	)	)	PUNCT
dpc-2053	118	20	were	be	AUX
dpc-2053	118	21	reported	report	VERB
dpc-2053	118	22	.	.	PUNCT
dpc-2053	119	1	specifically	specifically	ADV
dpc-2053	119	2	,	,	PUNCT
dpc-2053	119	3	a	a	DET
dpc-2053	119	4	single	single	ADJ
dpc-2053	119	5	case	case	NOUN
dpc-2053	119	6	of	of	ADP
dpc-2053	119	7	angioedema	angioedema	NOUN
dpc-2053	119	8	and	and	CCONJ
dpc-2053	119	9	1	1	NUM
dpc-2053	119	10	case	case	NOUN
dpc-2053	119	11	of	of	ADP
dpc-2053	119	12	respiratory	respiratory	ADJ
dpc-2053	119	13	crisis	crisis	NOUN
dpc-2053	119	14	have	have	AUX
dpc-2053	119	15	been	be	AUX
dpc-2053	119	16	documented	document	VERB
dpc-2053	119	17	,	,	PUNCT
dpc-2053	119	18	leading	lead	VERB
dpc-2053	119	19	to	to	ADP
dpc-2053	119	20	therapy	therapy	NOUN
dpc-2053	119	21	discontinuation	discontinuation	NOUN
dpc-2053	119	22	.	.	PUNCT
dpc-2053	120	1	other	other	ADJ
dpc-2053	120	2	reasons	reason	NOUN
dpc-2053	120	3	why	why	SCONJ
dpc-2053	120	4	patients	patient	NOUN
dpc-2053	120	5	interrupted	interrupt	VERB
dpc-2053	120	6	omalizumab	omalizumab	NOUN
dpc-2053	120	7	were	be	AUX
dpc-2053	120	8	ineffectiveness	ineffectiveness	NOUN
dpc-2053	120	9	or	or	CCONJ
dpc-2053	120	10	the	the	DET
dpc-2053	120	11	onset	onset	NOUN
dpc-2053	120	12	of	of	ADP
dpc-2053	120	13	disease	disease	NOUN
dpc-2053	120	14	that	that	PRON
dpc-2053	120	15	required	require	VERB
dpc-2053	120	16	hospitalization	hospitalization	NOUN
dpc-2053	120	17	(	(	PUNCT
dpc-2053	120	18	breast	breast	NOUN
dpc-2053	120	19	cancer	cancer	NOUN
dpc-2053	120	20	,	,	PUNCT
dpc-2053	120	21	atrial	atrial	ADJ
dpc-2053	120	22	fibrillation	fibrillation	NOUN
dpc-2053	120	23	,	,	PUNCT
dpc-2053	120	24	splenic	splenic	ADJ
dpc-2053	120	25	aneurysm	aneurysm	NOUN
dpc-2053	120	26	)	)	PUNCT
dpc-2053	120	27	.	.	PUNCT
dpc-2053	121	1	the	the	DET
dpc-2053	121	2	total	total	ADJ
dpc-2053	121	3	number	number	NOUN
dpc-2053	121	4	of	of	ADP
dpc-2053	121	5	patients	patient	NOUN
dpc-2053	121	6	who	who	PRON
dpc-2053	121	7	discontinued	discontinue	VERB
dpc-2053	121	8	the	the	DET
dpc-2053	121	9	first	first	ADJ
dpc-2053	121	10	course	course	NOUN
dpc-2053	121	11	of	of	ADP
dpc-2053	121	12	omalizumab	omalizumab	NOUN
dpc-2053	121	13	was	be	AUX
dpc-2053	121	14	10	10	NUM
dpc-2053	121	15	(	(	PUNCT
dpc-2053	121	16	25	25	NUM
dpc-2053	121	17	%	%	NOUN
dpc-2053	121	18	)	)	PUNCT
dpc-2053	121	19	.	.	PUNCT
dpc-2053	122	1	recent	recent	ADJ
dpc-2053	122	2	findings	finding	NOUN
dpc-2053	122	3	have	have	AUX
dpc-2053	122	4	shown	show	VERB
dpc-2053	122	5	an	an	DET
dpc-2053	122	6	increased	increase	VERB
dpc-2053	122	7	prevalence	prevalence	NOUN
dpc-2053	122	8	of	of	ADP
dpc-2053	122	9	metabolic	metabolic	NOUN
dpc-2053	122	10	syndrome	syndrome	NOUN
dpc-2053	122	11	among	among	ADP
dpc-2053	122	12	patients	patient	NOUN
dpc-2053	122	13	with	with	ADP
dpc-2053	122	14	csu	csu	PROPN
dpc-2053	122	15	,	,	PUNCT
dpc-2053	122	16	which	which	PRON
dpc-2053	122	17	is	be	AUX
dpc-2053	122	18	characterized	characterize	VERB
dpc-2053	122	19	by	by	ADP
dpc-2053	122	20	a	a	DET
dpc-2053	122	21	pro	pro	ADJ
dpc-2053	122	22	-	-	ADJ
dpc-2053	122	23	inflammatory	inflammatory	ADJ
dpc-2053	122	24	state	state	NOUN
dpc-2053	122	25	,	,	PUNCT
dpc-2053	122	26	increased	increase	VERB
dpc-2053	122	27	oxidative	oxidative	ADJ
dpc-2053	122	28	stress	stress	NOUN
dpc-2053	122	29	and	and	CCONJ
dpc-2053	122	30	alterations	alteration	NOUN
dpc-2053	122	31	in	in	ADP
dpc-2053	122	32	adipokine	adipokine	ADJ
dpc-2053	122	33	profile	profile	NOUN
dpc-2053	122	34	[	[	X
dpc-2053	122	35	11	11	NUM
dpc-2053	122	36	-	-	SYM
dpc-2053	122	37	13	13	NUM
dpc-2053	122	38	]	]	PUNCT
dpc-2053	122	39	.	.	PUNCT
dpc-2053	123	1	interestingly	interestingly	ADV
dpc-2053	123	2	,	,	PUNCT
dpc-2053	123	3	the	the	DET
dpc-2053	123	4	majority	majority	NOUN
dpc-2053	123	5	of	of	ADP
dpc-2053	123	6	patients	patient	NOUN
dpc-2053	123	7	(	(	PUNCT
dpc-2053	123	8	7/10	7/10	NUM
dpc-2053	123	9	)	)	PUNCT
dpc-2053	123	10	who	who	PRON
dpc-2053	123	11	did	do	AUX
dpc-2053	123	12	not	not	PART
dpc-2053	123	13	have	have	VERB
dpc-2053	123	14	a	a	DET
dpc-2053	123	15	response	response	NOUN
dpc-2053	123	16	to	to	ADP
dpc-2053	123	17	omalizumab	omalizumab	NOUN
dpc-2053	123	18	had	have	VERB
dpc-2053	123	19	a	a	DET
dpc-2053	123	20	high	high	ADJ
dpc-2053	123	21	bmi	bmi	NOUN
dpc-2053	123	22	(	(	PUNCT
dpc-2053	123	23	bmi	bmi	X
dpc-2053	123	24	>	>	X
dpc-2053	123	25	25	25	NUM
dpc-2053	123	26	kg	kg	PROPN
dpc-2053	123	27	/	/	SYM
dpc-2053	123	28	m2	m2	PROPN
dpc-2053	123	29	)	)	PUNCT
dpc-2053	123	30	,	,	PUNCT
dpc-2053	123	31	suggesting	suggest	VERB
dpc-2053	123	32	the	the	DET
dpc-2053	123	33	potential	potential	ADJ
dpc-2053	123	34	role	role	NOUN
dpc-2053	123	35	of	of	ADP
dpc-2053	123	36	adipokines	adipokine	NOUN
dpc-2053	123	37	in	in	ADP
dpc-2053	123	38	mast	mast	NOUN
dpc-2053	123	39	cells	cell	NOUN
dpc-2053	123	40	activation	activation	NOUN
dpc-2053	123	41	leading	lead	VERB
dpc-2053	123	42	to	to	ADP
dpc-2053	123	43	csu	csu	VERB
dpc-2053	123	44	worsening	worsen	VERB
dpc-2053	123	45	.	.	PUNCT
dpc-2053	124	1	however	however	ADV
dpc-2053	124	2	,	,	PUNCT
dpc-2053	124	3	the	the	DET
dpc-2053	124	4	high	high	ADJ
dpc-2053	124	5	body	body	NOUN
dpc-2053	124	6	weight	weight	NOUN
dpc-2053	124	7	may	may	AUX
dpc-2053	124	8	also	also	ADV
dpc-2053	124	9	influence	influence	VERB
dpc-2053	124	10	the	the	DET
dpc-2053	124	11	pharmacokinetics	pharmacokinetic	NOUN
dpc-2053	124	12	of	of	ADP
dpc-2053	124	13	the	the	DET
dpc-2053	124	14	drugs	drug	NOUN
dpc-2053	124	15	affecting	affect	VERB
dpc-2053	124	16	the	the	DET
dpc-2053	124	17	apparent	apparent	ADJ
dpc-2053	124	18	volume	volume	NOUN
dpc-2053	124	19	of	of	ADP
dpc-2053	124	20	distribution	distribution	NOUN
dpc-2053	124	21	of	of	ADP
dpc-2053	124	22	the	the	DET
dpc-2053	124	23	drugs	drug	NOUN
dpc-2053	124	24	,	,	PUNCT
dpc-2053	124	25	as	as	SCONJ
dpc-2053	124	26	documented	document	VERB
dpc-2053	124	27	in	in	ADP
dpc-2053	124	28	other	other	ADJ
dpc-2053	124	29	studies	study	NOUN
dpc-2053	124	30	on	on	ADP
dpc-2053	124	31	biological	biological	ADJ
dpc-2053	124	32	treatments	treatment	NOUN
dpc-2053	124	33	[	[	PUNCT
dpc-2053	124	34	13	13	NUM
dpc-2053	124	35	-	-	SYM
dpc-2053	124	36	15	15	NUM
dpc-2053	124	37	]	]	PUNCT
dpc-2053	124	38	.	.	PUNCT
dpc-2053	125	1	the	the	DET
dpc-2053	125	2	recommended	recommend	VERB
dpc-2053	125	3	dose	dose	NOUN
dpc-2053	125	4	of	of	ADP
dpc-2053	125	5	omalizumab	omalizumab	NOUN
dpc-2053	125	6	for	for	ADP
dpc-2053	125	7	the	the	DET
dpc-2053	125	8	treatment	treatment	NOUN
dpc-2053	125	9	of	of	ADP
dpc-2053	125	10	csu	csu	PROPN
dpc-2053	125	11	is	be	AUX
dpc-2053	125	12	300	300	NUM
dpc-2053	125	13	mg	mg	NOUN
dpc-2053	125	14	every	every	DET
dpc-2053	125	15	4	4	NUM
dpc-2053	125	16	weeks	week	NOUN
dpc-2053	125	17	,	,	PUNCT
dpc-2053	125	18	but	but	CCONJ
dpc-2053	125	19	there	there	PRON
dpc-2053	125	20	is	be	VERB
dpc-2053	125	21	no	no	DET
dpc-2053	125	22	recommendation	recommendation	NOUN
dpc-2053	125	23	for	for	ADP
dpc-2053	125	24	patients	patient	NOUN
dpc-2053	125	25	who	who	PRON
dpc-2053	125	26	do	do	AUX
dpc-2053	125	27	not	not	PART
dpc-2053	125	28	benefit	benefit	VERB
dpc-2053	125	29	from	from	ADP
dpc-2053	125	30	this	this	DET
dpc-2053	125	31	dose	dose	NOUN
dpc-2053	125	32	.	.	PUNCT
dpc-2053	126	1	while	while	SCONJ
dpc-2053	126	2	original	original	ADJ
dpc-2053	126	3	article	article	NOUN
dpc-2053	126	4	|	|	ADV
dpc-2053	126	5	dermatol	dermatol	ADJ
dpc-2053	126	6	pract	pract	NOUN
dpc-2053	126	7	concept	concept	NOUN
dpc-2053	126	8	.	.	PUNCT
dpc-2053	127	1	2022;12(4):e2022148	2022;12(4):e2022148	NUM
dpc-2053	127	2	5	5	NUM
dpc-2053	127	3	real	real	ADJ
dpc-2053	127	4	-	-	PUNCT
dpc-2053	127	5	life	life	NOUN
dpc-2053	127	6	effectiveness	effectiveness	NOUN
dpc-2053	127	7	.	.	PUNCT
dpc-2053	128	1	ther	ther	PROPN
dpc-2053	128	2	adv	adv	PROPN
dpc-2053	128	3	respir	respir	VERB
dpc-2053	128	4	dis	dis	PROPN
dpc-2053	128	5	.	.	PUNCT
dpc-2053	129	1	2018;12:1	2018;12:1	NUM
dpc-2053	129	2	-	-	SYM
dpc-2053	129	3	16	16	NUM
dpc-2053	129	4	.	.	PUNCT
dpc-2053	130	1	doi:10.1177/1753466618810192	doi:10.1177/1753466618810192	X
dpc-2053	130	2	.	.	PUNCT
dpc-2053	131	1	pmid	pmid	NOUN
dpc-2053	131	2	:	:	PUNCT
dpc-2053	131	3	30400762	30400762	NUM
dpc-2053	131	4	;	;	PUNCT
dpc-2053	131	5	pmcid	pmcid	ADJ
dpc-2053	131	6	:	:	PUNCT
dpc-2053	131	7	pmc6236630	pmc6236630	ADJ
dpc-2053	131	8	.	.	PUNCT
dpc-2053	132	1	6	6	X
dpc-2053	132	2	.	.	X
dpc-2053	132	3	maurer	maurer	PROPN
dpc-2053	132	4	m	m	PROPN
dpc-2053	132	5	,	,	PUNCT
dpc-2053	132	6	rosén	rosén	VERB
dpc-2053	132	7	k	k	PROPN
dpc-2053	132	8	,	,	PUNCT
dpc-2053	132	9	hsieh	hsieh	PROPN
dpc-2053	132	10	h	h	PROPN
dpc-2053	132	11	-	-	PUNCT
dpc-2053	132	12	j	j	PROPN
dpc-2053	132	13	,	,	PUNCT
dpc-2053	132	14	et	et	PROPN
dpc-2053	132	15	al	al	PROPN
dpc-2053	132	16	.	.	PROPN
dpc-2053	132	17	omalizumab	omalizumab	NOUN
dpc-2053	132	18	for	for	ADP
dpc-2053	132	19	the	the	DET
dpc-2053	132	20	treatment	treatment	NOUN
dpc-2053	132	21	of	of	ADP
dpc-2053	132	22	chronic	chronic	ADJ
dpc-2053	132	23	idiopathic	idiopathic	ADJ
dpc-2053	132	24	or	or	CCONJ
dpc-2053	132	25	spontaneous	spontaneous	ADJ
dpc-2053	132	26	urticaria	urticaria	NOUN
dpc-2053	132	27	.	.	PUNCT
dpc-2053	133	1	n	n	PROPN
dpc-2053	133	2	engl	engl	PROPN
dpc-2053	133	3	j	j	PROPN
dpc-2053	133	4	med	med	PROPN
dpc-2053	133	5	.	.	PUNCT
dpc-2053	134	1	2013;368(10):924	2013;368(10):924	NUM
dpc-2053	134	2	-	-	SYM
dpc-2053	134	3	935	935	NUM
dpc-2053	134	4	.	.	PUNCT
dpc-2053	134	5	doi:10.1056	doi:10.1056	PROPN
dpc-2053	134	6	/	/	SYM
dpc-2053	134	7	nejmoa1215372	nejmoa1215372	PROPN
dpc-2053	134	8	.	.	PUNCT
dpc-2053	135	1	pmid	pmid	NOUN
dpc-2053	135	2	:	:	PUNCT
dpc-2053	135	3	23432142	23432142	NUM
dpc-2053	135	4	.	.	PUNCT
dpc-2053	136	1	7	7	X
dpc-2053	136	2	.	.	X
dpc-2053	136	3	saini	saini	PROPN
dpc-2053	136	4	ss	ss	PROPN
dpc-2053	136	5	,	,	PUNCT
dpc-2053	136	6	bindslev	bindslev	NOUN
dpc-2053	136	7	-	-	PUNCT
dpc-2053	136	8	jensen	jensen	PROPN
dpc-2053	136	9	c	c	PROPN
dpc-2053	136	10	,	,	PUNCT
dpc-2053	136	11	maurer	maurer	PROPN
dpc-2053	136	12	m	m	PROPN
dpc-2053	136	13	,	,	PUNCT
dpc-2053	136	14	et	et	PROPN
dpc-2053	136	15	al	al	PROPN
dpc-2053	136	16	.	.	PROPN
dpc-2053	136	17	efficacy	efficacy	NOUN
dpc-2053	136	18	and	and	CCONJ
dpc-2053	136	19	safety	safety	NOUN
dpc-2053	136	20	of	of	ADP
dpc-2053	136	21	omalizumab	omalizumab	NOUN
dpc-2053	136	22	in	in	ADP
dpc-2053	136	23	patients	patient	NOUN
dpc-2053	136	24	with	with	ADP
dpc-2053	136	25	chronic	chronic	ADJ
dpc-2053	136	26	idiopathic/	idiopathic/	NUM
dpc-2053	136	27	spontaneous	spontaneous	ADJ
dpc-2053	136	28	urticaria	urticaria	NOUN
dpc-2053	136	29	who	who	PRON
dpc-2053	136	30	remain	remain	VERB
dpc-2053	136	31	symptomatic	symptomatic	ADJ
dpc-2053	136	32	on	on	ADP
dpc-2053	136	33	h1	h1	PROPN
dpc-2053	136	34	antihistamines	antihistamine	NOUN
dpc-2053	136	35	:	:	PUNCT
dpc-2053	136	36	a	a	DET
dpc-2053	136	37	randomized	randomized	ADJ
dpc-2053	136	38	,	,	PUNCT
dpc-2053	136	39	placebo	placebo	NOUN
dpc-2053	136	40	-	-	PUNCT
dpc-2053	136	41	controlled	control	VERB
dpc-2053	136	42	study	study	NOUN
dpc-2053	136	43	.	.	PUNCT
dpc-2053	137	1	j	j	PROPN
dpc-2053	137	2	invest	invest	VERB
dpc-2053	137	3	dermatol.2015;135(1):67	dermatol.2015;135(1):67	PROPN
dpc-2053	137	4	-	-	PUNCT
dpc-2053	137	5	75	75	NUM
dpc-2053	137	6	.	.	PUNCT
dpc-2053	138	1	doi:10.1038	doi:10.1038	NOUN
dpc-2053	138	2	/	/	SYM
dpc-2053	138	3	jid.2014.306	jid.2014.306	NOUN
dpc-2053	138	4	.	.	PUNCT
dpc-2053	139	1	pmid	pmid	NOUN
dpc-2053	139	2	:	:	PUNCT
dpc-2053	139	3	25046337	25046337	NUM
dpc-2053	139	4	.	.	PUNCT
dpc-2053	140	1	pmcid	pmcid	NOUN
dpc-2053	140	2	:	:	PUNCT
dpc-2053	140	3	pmc4269803	pmc4269803	NOUN
dpc-2053	140	4	.	.	PUNCT
dpc-2053	141	1	8	8	X
dpc-2053	141	2	.	.	X
dpc-2053	142	1	kaplan	kaplan	PROPN
dpc-2053	142	2	a	a	PROPN
dpc-2053	142	3	,	,	PUNCT
dpc-2053	142	4	ledford	ledford	PROPN
dpc-2053	142	5	d	d	PROPN
dpc-2053	142	6	,	,	PUNCT
dpc-2053	142	7	ashby	ashby	PROPN
dpc-2053	142	8	m	m	PROPN
dpc-2053	142	9	,	,	PUNCT
dpc-2053	142	10	et	et	PROPN
dpc-2053	142	11	al	al	PROPN
dpc-2053	142	12	.	.	PROPN
dpc-2053	142	13	omalizumab	omalizumab	NOUN
dpc-2053	142	14	in	in	ADP
dpc-2053	142	15	patients	patient	NOUN
dpc-2053	142	16	with	with	ADP
dpc-2053	142	17	symptomatic	symptomatic	ADJ
dpc-2053	142	18	chronic	chronic	ADJ
dpc-2053	142	19	idiopathic	idiopathic	ADJ
dpc-2053	142	20	/	/	SYM
dpc-2053	142	21	spontaneous	spontaneous	ADJ
dpc-2053	142	22	urticaria	urticaria	NOUN
dpc-2053	142	23	despite	despite	SCONJ
dpc-2053	142	24	standard	standard	ADJ
dpc-2053	142	25	combination	combination	NOUN
dpc-2053	142	26	therapy	therapy	NOUN
dpc-2053	142	27	.	.	PUNCT
dpc-2053	143	1	j	j	PROPN
dpc-2053	143	2	allergy	allergy	PROPN
dpc-2053	143	3	clin	clin	PROPN
dpc-2053	143	4	immunol	immunol	PROPN
dpc-2053	143	5	.	.	PUNCT
dpc-2053	144	1	2013;132(1):101	2013;132(1):101	NUM
dpc-2053	144	2	-	-	SYM
dpc-2053	144	3	109	109	NUM
dpc-2053	144	4	.	.	PUNCT
dpc-2053	144	5	doi	doi	NOUN
dpc-2053	144	6	:	:	PUNCT
dpc-2053	144	7	10.1016	10.1016	NUM
dpc-2053	144	8	/	/	SYM
dpc-2053	144	9	j.jaci.2013.05.013	j.jaci.2013.05.013	PROPN
dpc-2053	144	10	.	.	PUNCT
dpc-2053	145	1	pmid	pmid	NOUN
dpc-2053	145	2	:	:	PUNCT
dpc-2053	145	3	23810097	23810097	NUM
dpc-2053	145	4	.	.	PUNCT
dpc-2053	146	1	9	9	X
dpc-2053	146	2	.	.	X
dpc-2053	146	3	goldstein	goldstein	PROPN
dpc-2053	146	4	s	s	PROPN
dpc-2053	146	5	,	,	PUNCT
dpc-2053	146	6	gabriel	gabriel	PROPN
dpc-2053	146	7	s	s	PROPN
dpc-2053	146	8	,	,	PUNCT
dpc-2053	146	9	kianifard	kianifard	ADJ
dpc-2053	146	10	f	f	PROPN
dpc-2053	146	11	,	,	PUNCT
dpc-2053	146	12	ortiz	ortiz	PROPN
dpc-2053	146	13	b	b	PROPN
dpc-2053	146	14	,	,	PUNCT
dpc-2053	146	15	skoner	skoner	PROPN
dpc-2053	146	16	dp	dp	PROPN
dpc-2053	146	17	.	.	PUNCT
dpc-2053	147	1	clinical	clinical	ADJ
dpc-2053	147	2	features	feature	NOUN
dpc-2053	147	3	of	of	ADP
dpc-2053	147	4	adolescents	adolescent	NOUN
dpc-2053	147	5	with	with	ADP
dpc-2053	147	6	chronic	chronic	ADJ
dpc-2053	147	7	idiopathic	idiopathic	ADJ
dpc-2053	147	8	or	or	CCONJ
dpc-2053	147	9	spontaneous	spontaneous	ADJ
dpc-2053	147	10	urticaria	urticaria	NOUN
dpc-2053	147	11	:	:	PUNCT
dpc-2053	147	12	review	review	NOUN
dpc-2053	147	13	of	of	ADP
dpc-2053	147	14	omalizumab	omalizumab	NOUN
dpc-2053	147	15	clinical	clinical	ADJ
dpc-2053	147	16	trials	trial	NOUN
dpc-2053	147	17	.	.	PUNCT
dpc-2053	148	1	ann	ann	PROPN
dpc-2053	148	2	allergy	allergy	PROPN
dpc-2053	148	3	asthma	asthma	PROPN
dpc-2053	148	4	immunol	immunol	PROPN
dpc-2053	148	5	.	.	PUNCT
dpc-2053	149	1	2017;118(4	2017;118(4	NUM
dpc-2053	149	2	):	):	PUNCT
dpc-2053	149	3	500–504	500–504	NUM
dpc-2053	149	4	.	.	PUNCT
dpc-2053	149	5	doi:10.1016	doi:10.1016	PROPN
dpc-2053	149	6	/	/	SYM
dpc-2053	149	7	j.	j.	PROPN
dpc-2053	149	8	anai.2017.02.003	anai.2017.02.003	PROPN
dpc-2053	149	9	.	.	PUNCT
dpc-2053	150	1	pmid	pmid	NOUN
dpc-2053	150	2	:	:	PUNCT
dpc-2053	150	3	28390587	28390587	NUM
dpc-2053	150	4	.	.	PUNCT
dpc-2053	151	1	10	10	NUM
dpc-2053	151	2	.	.	X
dpc-2053	151	3	mckeage	mckeage	PROPN
dpc-2053	151	4	k.	k.	PROPN
dpc-2053	151	5	omalizumab	omalizumab	PROPN
dpc-2053	151	6	:	:	PUNCT
dpc-2053	151	7	a	a	DET
dpc-2053	151	8	review	review	NOUN
dpc-2053	151	9	of	of	ADP
dpc-2053	151	10	its	its	PRON
dpc-2053	151	11	use	use	NOUN
dpc-2053	151	12	in	in	ADP
dpc-2053	151	13	patients	patient	NOUN
dpc-2053	151	14	with	with	ADP
dpc-2053	151	15	severe	severe	ADJ
dpc-2053	151	16	persistent	persistent	ADJ
dpc-2053	151	17	allergic	allergic	ADJ
dpc-2053	151	18	asthma	asthma	NOUN
dpc-2053	151	19	.	.	PUNCT
dpc-2053	152	1	drugs	drug	NOUN
dpc-2053	152	2	.	.	PUNCT
dpc-2053	153	1	2013;73(11):11971212	2013;73(11):11971212	X
dpc-2053	153	2	.	.	PUNCT
dpc-2053	153	3	doi	doi	NOUN
dpc-2053	153	4	:	:	PUNCT
dpc-2053	153	5	10.1007	10.1007	NUM
dpc-2053	153	6	/	/	SYM
dpc-2053	153	7	s40265	s40265	NOUN
dpc-2053	153	8	-	-	PUNCT
dpc-2053	153	9	013	013	NUM
dpc-2053	153	10	-	-	PUNCT
dpc-2053	153	11	0085	0085	NUM
dpc-2053	153	12	-	-	PUNCT
dpc-2053	153	13	4	4	NUM
dpc-2053	153	14	.	.	PUNCT
dpc-2053	154	1	pmid	pmid	NOUN
dpc-2053	154	2	:	:	PUNCT
dpc-2053	154	3	23812924	23812924	NUM
dpc-2053	154	4	.	.	PUNCT
dpc-2053	155	1	11	11	NUM
dpc-2053	155	2	.	.	X
dpc-2053	155	3	trinh	trinh	PROPN
dpc-2053	155	4	hk	hk	PROPN
dpc-2053	155	5	,	,	PUNCT
dpc-2053	155	6	pham	pham	PROPN
dpc-2053	155	7	dl	dl	PROPN
dpc-2053	155	8	,	,	PUNCT
dpc-2053	155	9	ban	ban	NOUN
dpc-2053	155	10	gy	gy	NOUN
dpc-2053	155	11	,	,	PUNCT
dpc-2053	155	12	lee	lee	PROPN
dpc-2053	155	13	hy	hy	PROPN
dpc-2053	155	14	,	,	PUNCT
dpc-2053	155	15	park	park	PROPN
dpc-2053	155	16	hs	hs	PROPN
dpc-2053	155	17	,	,	PUNCT
dpc-2053	155	18	ye	ye	PROPN
dpc-2053	155	19	ym	ym	PROPN
dpc-2053	155	20	.	.	PUNCT
dpc-2053	155	21	altered	alter	VERB
dpc-2053	155	22	systemic	systemic	ADJ
dpc-2053	155	23	adipokines	adipokine	NOUN
dpc-2053	155	24	in	in	ADP
dpc-2053	155	25	patients	patient	NOUN
dpc-2053	155	26	with	with	ADP
dpc-2053	155	27	chronic	chronic	ADJ
dpc-2053	155	28	urticaria	urticaria	NOUN
dpc-2053	155	29	.	.	PUNCT
dpc-2053	156	1	int	int	PROPN
dpc-2053	156	2	arch	arch	ADJ
dpc-2053	156	3	allergy	allergy	PROPN
dpc-2053	156	4	immunol	immunol	NOUN
dpc-2053	156	5	.	.	PUNCT
dpc-2053	157	1	2016;171(2):102	2016;171(2):102	NUM
dpc-2053	157	2	-	-	SYM
dpc-2053	157	3	110	110	NUM
dpc-2053	157	4	.	.	PUNCT
dpc-2053	157	5	doi	doi	NOUN
dpc-2053	157	6	:	:	PUNCT
dpc-2053	157	7	10.1159/000452626	10.1159/000452626	NUM
dpc-2053	157	8	.	.	PUNCT
dpc-2053	158	1	pmid	pmid	NOUN
dpc-2053	158	2	:	:	PUNCT
dpc-2053	158	3	27902979	27902979	NUM
dpc-2053	158	4	.	.	PUNCT
dpc-2053	159	1	12	12	NUM
dpc-2053	159	2	.	.	PUNCT
dpc-2053	159	3	vena	vena	PROPN
dpc-2053	159	4	ga	ga	PROPN
dpc-2053	159	5	,	,	PUNCT
dpc-2053	159	6	cassano	cassano	PROPN
dpc-2053	159	7	n.	n.	PROPN
dpc-2053	160	1	the	the	DET
dpc-2053	160	2	link	link	NOUN
dpc-2053	160	3	between	between	ADP
dpc-2053	160	4	chronic	chronic	ADJ
dpc-2053	160	5	spontaneous	spontaneous	ADJ
dpc-2053	160	6	urticaria	urticaria	NOUN
dpc-2053	160	7	and	and	CCONJ
dpc-2053	160	8	metabolic	metabolic	NOUN
dpc-2053	160	9	syndrome	syndrome	NOUN
dpc-2053	160	10	.	.	PUNCT
dpc-2053	161	1	eur	eur	PROPN
dpc-2053	161	2	ann	ann	PROPN
dpc-2053	161	3	allergy	allergy	PROPN
dpc-2053	161	4	clin	clin	PROPN
dpc-2053	161	5	immunol	immunol	NOUN
dpc-2053	161	6	.	.	PUNCT
dpc-2053	162	1	2017;49(5):208	2017;49(5):208	NUM
dpc-2053	162	2	-	-	PUNCT
dpc-2053	162	3	212	212	NUM
dpc-2053	162	4	.	.	PUNCT
dpc-2053	163	1	doi	doi	NOUN
dpc-2053	163	2	:	:	PUNCT
dpc-2053	163	3	10.23822	10.23822	NUM
dpc-2053	163	4	/	/	SYM
dpc-2053	163	5	eurann	eurann	PROPN
dpc-2053	163	6	aci.17641489.12	aci.17641489.12	PROPN
dpc-2053	163	7	.	.	NOUN
dpc-2053	163	8	pmid	pmid	PROPN
dpc-2053	163	9	:	:	PUNCT
dpc-2053	163	10	28884987	28884987	NUM
dpc-2053	163	11	.	.	PUNCT
dpc-2053	164	1	13	13	NUM
dpc-2053	164	2	.	.	PUNCT
dpc-2053	164	3	magen	magen	PROPN
dpc-2053	164	4	e	e	PROPN
dpc-2053	164	5	,	,	PUNCT
dpc-2053	164	6	chikovani	chikovani	PROPN
dpc-2053	164	7	t	t	PROPN
dpc-2053	164	8	,	,	PUNCT
dpc-2053	164	9	waitman	waitman	NOUN
dpc-2053	164	10	da	da	PROPN
dpc-2053	164	11	,	,	PUNCT
dpc-2053	164	12	kahan	kahan	PROPN
dpc-2053	164	13	nr	nr	PROPN
dpc-2053	164	14	.	.	PROPN
dpc-2053	164	15	factors	factor	NOUN
dpc-2053	164	16	related	relate	VERB
dpc-2053	164	17	to	to	ADP
dpc-2053	164	18	omalizumab	omalizumab	NOUN
dpc-2053	164	19	resistance	resistance	NOUN
dpc-2053	164	20	in	in	ADP
dpc-2053	164	21	chronic	chronic	ADJ
dpc-2053	164	22	spontaneous	spontaneous	ADJ
dpc-2053	164	23	urticaria	urticaria	NOUN
dpc-2053	164	24	.	.	PUNCT
dpc-2053	165	1	allergy	allergy	PROPN
dpc-2053	165	2	asthma	asthma	PROPN
dpc-2053	165	3	proc	proc	PROPN
dpc-2053	165	4	.	.	PUNCT
dpc-2053	166	1	2019;40(4):273	2019;40(4):273	NUM
dpc-2053	166	2	-	-	PUNCT
dpc-2053	166	3	278	278	NUM
dpc-2053	166	4	.	.	PUNCT
dpc-2053	167	1	doi	doi	NOUN
dpc-2053	167	2	:	:	PUNCT
dpc-2053	167	3	10.2500/	10.2500/	NUM
dpc-2053	167	4	aap.2019.40.4230	aap.2019.40.4230	PROPN
dpc-2053	167	5	.	.	PUNCT
dpc-2053	168	1	pmid	pmid	PROPN
dpc-2053	168	2	:	:	PUNCT
dpc-2053	168	3	31262381	31262381	NUM
dpc-2053	168	4	.	.	PUNCT
dpc-2053	169	1	14	14	NUM
dpc-2053	169	2	.	.	PUNCT
dpc-2053	170	1	pirro	pirro	PROPN
dpc-2053	170	2	f	f	PROPN
dpc-2053	170	3	,	,	PUNCT
dpc-2053	170	4	caldarola	caldarola	PROPN
dpc-2053	170	5	g	g	PROPN
dpc-2053	170	6	,	,	PUNCT
dpc-2053	170	7	chiricozzi	chiricozzi	NOUN
dpc-2053	170	8	a	a	NOUN
dpc-2053	170	9	,	,	PUNCT
dpc-2053	170	10	et	et	PROPN
dpc-2053	170	11	al	al	PROPN
dpc-2053	170	12	.	.	PROPN
dpc-2053	170	13	impact	impact	NOUN
dpc-2053	170	14	of	of	ADP
dpc-2053	170	15	body	body	NOUN
dpc-2053	170	16	mass	mass	NOUN
dpc-2053	170	17	index	index	NOUN
dpc-2053	170	18	on	on	ADP
dpc-2053	170	19	the	the	DET
dpc-2053	170	20	efficacy	efficacy	NOUN
dpc-2053	170	21	of	of	ADP
dpc-2053	170	22	biological	biological	ADJ
dpc-2053	170	23	therapies	therapy	NOUN
dpc-2053	170	24	in	in	ADP
dpc-2053	170	25	patients	patient	NOUN
dpc-2053	170	26	with	with	ADP
dpc-2053	170	27	psoriasis	psoriasis	NOUN
dpc-2053	170	28	:	:	PUNCT
dpc-2053	170	29	a	a	DET
dpc-2053	170	30	real	real	ADJ
dpc-2053	170	31	-	-	PUNCT
dpc-2053	170	32	world	world	NOUN
dpc-2053	170	33	study	study	NOUN
dpc-2053	170	34	.	.	PUNCT
dpc-2053	171	1	clin	clin	PROPN
dpc-2053	171	2	drug	drug	PROPN
dpc-2053	171	3	investig	investig	PROPN
dpc-2053	171	4	.	.	PUNCT
dpc-2053	171	5	2021;41(10):917	2021;41(10):917	PROPN
dpc-2053	171	6	-	-	SYM
dpc-2053	171	7	925	925	NUM
dpc-2053	171	8	.	.	PUNCT
dpc-2053	172	1	doi	doi	NOUN
dpc-2053	172	2	:	:	PUNCT
dpc-2053	172	3	10.1007	10.1007	NUM
dpc-2053	172	4	/	/	SYM
dpc-2053	172	5	s40261	s40261	PROPN
dpc-2053	172	6	-	-	PUNCT
dpc-2053	172	7	021	021	NUM
dpc-2053	172	8	-	-	PUNCT
dpc-2053	172	9	01080	01080	NUM
dpc-2053	172	10	-	-	PUNCT
dpc-2053	172	11	z.	z.	PROPN
dpc-2053	172	12	pmid	pmid	PROPN
dpc-2053	172	13	:	:	PUNCT
dpc-2053	172	14	34537921	34537921	NUM
dpc-2053	172	15	.	.	PUNCT
dpc-2053	173	1	pmcid	pmcid	ADJ
dpc-2053	173	2	:	:	PUNCT
dpc-2053	173	3	pmc8481196	pmc8481196	NOUN
dpc-2053	173	4	.	.	PUNCT
dpc-2053	174	1	15	15	X
dpc-2053	174	2	.	.	PUNCT
dpc-2053	175	1	hansel	hansel	PROPN
dpc-2053	175	2	k	k	PROPN
dpc-2053	175	3	,	,	PUNCT
dpc-2053	175	4	bianchi	bianchi	PROPN
dpc-2053	175	5	l	l	PROPN
dpc-2053	175	6	,	,	PUNCT
dpc-2053	175	7	lanza	lanza	NOUN
dpc-2053	175	8	f	f	PROPN
dpc-2053	175	9	,	,	PUNCT
dpc-2053	175	10	bini	bini	PROPN
dpc-2053	175	11	v	v	PROPN
dpc-2053	175	12	,	,	PUNCT
dpc-2053	175	13	stingeni	stingeni	ADJ
dpc-2053	175	14	l.	l.	PROPN
dpc-2053	175	15	adalimumab	adalimumab	PROPN
dpc-2053	175	16	dose	dose	PROPN
dpc-2053	175	17	tapering	taper	VERB
dpc-2053	175	18	in	in	ADP
dpc-2053	175	19	psoriasis	psoriasis	NOUN
dpc-2053	175	20	:	:	PUNCT
dpc-2053	175	21	predictive	predictive	ADJ
dpc-2053	175	22	factors	factor	NOUN
dpc-2053	175	23	for	for	ADP
dpc-2053	175	24	maintenance	maintenance	NOUN
dpc-2053	175	25	of	of	ADP
dpc-2053	175	26	complete	complete	ADJ
dpc-2053	175	27	clearance	clearance	NOUN
dpc-2053	175	28	.	.	PUNCT
dpc-2053	176	1	acta	acta	PROPN
dpc-2053	176	2	derm	derm	PROPN
dpc-2053	176	3	venereol	venereol	NOUN
dpc-2053	176	4	.	.	PUNCT
dpc-2053	177	1	2017;97(3):346	2017;97(3):346	NUM
dpc-2053	177	2	-	-	SYM
dpc-2053	177	3	350	350	NUM
dpc-2053	177	4	.	.	PUNCT
dpc-2053	178	1	doi	doi	NOUN
dpc-2053	178	2	:	:	PUNCT
dpc-2053	178	3	10.2340/00015555	10.2340/00015555	NUM
dpc-2053	178	4	-	-	SYM
dpc-2053	178	5	2571	2571	NUM
dpc-2053	178	6	.	.	PUNCT
dpc-2053	179	1	pmid	pmid	NOUN
dpc-2053	179	2	:	:	PUNCT
dpc-2053	179	3	27868145	27868145	NUM
dpc-2053	179	4	.	.	PUNCT
dpc-2053	180	1	16	16	NUM
dpc-2053	180	2	.	.	PUNCT
dpc-2053	181	1	metz	metz	PROPN
dpc-2053	181	2	m	m	PROPN
dpc-2053	181	3	,	,	PUNCT
dpc-2053	181	4	vadasz	vadasz	PROPN
dpc-2053	181	5	z	z	PROPN
dpc-2053	181	6	,	,	PUNCT
dpc-2053	181	7	kocatürk	kocatürk	PROPN
dpc-2053	181	8	e	e	PROPN
dpc-2053	181	9	,	,	PUNCT
dpc-2053	181	10	giménez	giménez	PROPN
dpc-2053	181	11	-	-	PUNCT
dpc-2053	181	12	arnau	arnau	PROPN
dpc-2053	181	13	am	be	AUX
dpc-2053	181	14	.	.	PUNCT
dpc-2053	182	1	omalizumab	omalizumab	NOUN
dpc-2053	182	2	updosing	updose	VERB
dpc-2053	182	3	in	in	ADP
dpc-2053	182	4	chronic	chronic	ADJ
dpc-2053	182	5	spontaneous	spontaneous	ADJ
dpc-2053	182	6	urticaria	urticaria	NOUN
dpc-2053	182	7	:	:	PUNCT
dpc-2053	182	8	an	an	DET
dpc-2053	182	9	overview	overview	NOUN
dpc-2053	182	10	of	of	ADP
dpc-2053	182	11	real	real	ADJ
dpc-2053	182	12	-	-	PUNCT
dpc-2053	182	13	world	world	NOUN
dpc-2053	182	14	evidence	evidence	NOUN
dpc-2053	182	15	.	.	PUNCT
dpc-2053	183	1	clin	clin	PROPN
dpc-2053	183	2	rev	rev	PROPN
dpc-2053	183	3	allergy	allergy	PROPN
dpc-2053	183	4	immunol	immunol	PROPN
dpc-2053	183	5	.	.	PUNCT
dpc-2053	184	1	2020;59(1):38	2020;59(1):38	NUM
dpc-2053	184	2	-	-	SYM
dpc-2053	184	3	45	45	NUM
dpc-2053	184	4	.	.	PUNCT
dpc-2053	185	1	doi:10.1007	doi:10.1007	VERB
dpc-2053	185	2	/	/	SYM
dpc-2053	186	1	s12016	s12016	PROPN
dpc-2053	186	2	-	-	PUNCT
dpc-2053	186	3	020	020	NUM
dpc-2053	186	4	-	-	PUNCT
dpc-2053	186	5	08794	08794	NUM
dpc-2053	186	6	-	-	PUNCT
dpc-2053	186	7	6	6	NUM
dpc-2053	186	8	.	.	PUNCT
dpc-2053	187	1	pmid	pmid	NOUN
dpc-2053	187	2	:	:	PUNCT
dpc-2053	187	3	32418171	32418171	NUM
dpc-2053	187	4	.	.	PUNCT
dpc-2053	188	1	pmcid	pmcid	NOUN
dpc-2053	188	2	:	:	PUNCT
dpc-2053	188	3	pmc7351799	pmc7351799	NOUN
dpc-2053	188	4	.	.	PUNCT
dpc-2053	189	1	17	17	NUM
dpc-2053	189	2	.	.	PUNCT
dpc-2053	190	1	kocatürk	kocatürk	PROPN
dpc-2053	191	1	e	e	PROPN
dpc-2053	191	2	,	,	PUNCT
dpc-2053	191	3	deza	deza	ADV
dpc-2053	191	4	g	g	NOUN
dpc-2053	191	5	,	,	PUNCT
dpc-2053	191	6	kızıltaç	kızıltaç	ADJ
dpc-2053	191	7	k	k	NOUN
dpc-2053	191	8	,	,	PUNCT
dpc-2053	191	9	giménez	giménez	PROPN
dpc-2053	191	10	-	-	PUNCT
dpc-2053	191	11	arnau	arnau	PROPN
dpc-2053	191	12	am	be	AUX
dpc-2053	191	13	:	:	PUNCT
dpc-2053	191	14	omalizumab	omalizumab	NOUN
dpc-2053	191	15	updosing	updose	VERB
dpc-2053	191	16	for	for	ADP
dpc-2053	191	17	better	well	ADJ
dpc-2053	191	18	disease	disease	NOUN
dpc-2053	191	19	control	control	NOUN
dpc-2053	191	20	in	in	ADP
dpc-2053	191	21	chronic	chronic	ADJ
dpc-2053	191	22	spontaneous	spontaneous	ADJ
dpc-2053	191	23	urticaria	urticaria	NOUN
dpc-2053	191	24	patients	patient	NOUN
dpc-2053	191	25	.	.	PUNCT
dpc-2053	192	1	int	int	PROPN
dpc-2053	192	2	arch	arch	ADJ
dpc-2053	192	3	allergy	allergy	PROPN
dpc-2053	192	4	immunol	immunol	NOUN
dpc-2053	192	5	.	.	PUNCT
dpc-2053	193	1	2018;177(4):360	2018;177(4):360	NUM
dpc-2053	193	2	-	-	SYM
dpc-2053	193	3	364	364	NUM
dpc-2053	193	4	.	.	PUNCT
dpc-2053	193	5	doi	doi	NOUN
dpc-2053	193	6	:	:	PUNCT
dpc-2053	193	7	10.1159/000491530	10.1159/000491530	NUM
dpc-2053	193	8	.	.	PUNCT
dpc-2053	194	1	pmid	pmid	NOUN
dpc-2053	194	2	:	:	PUNCT
dpc-2053	194	3	30130798	30130798	NUM
dpc-2053	194	4	.	.	PUNCT
dpc-2053	195	1	6	6	NUM
dpc-2053	195	2	original	original	ADJ
dpc-2053	195	3	article	article	NOUN
dpc-2053	195	4	|	|	ADV
dpc-2053	195	5	dermatol	dermatol	ADJ
dpc-2053	195	6	pract	pract	NOUN
dpc-2053	195	7	concept	concept	NOUN
dpc-2053	195	8	.	.	PUNCT
dpc-2053	196	1	2022;12(4):e2022148	2022;12(4):e2022148	NUM
dpc-2053	196	2	18	18	NUM
dpc-2053	196	3	.	.	PUNCT
dpc-2053	197	1	marzano	marzano	PROPN
dpc-2053	197	2	av	av	PROPN
dpc-2053	197	3	,	,	PUNCT
dpc-2053	197	4	genovese	genovese	NOUN
dpc-2053	197	5	g	g	NOUN
dpc-2053	197	6	,	,	PUNCT
dpc-2053	197	7	casazza	casazza	NOUN
dpc-2053	197	8	g	g	NOUN
dpc-2053	197	9	,	,	PUNCT
dpc-2053	197	10	et	et	PROPN
dpc-2053	197	11	al	al	PROPN
dpc-2053	197	12	.	.	PUNCT
dpc-2053	197	13	predictors	predictor	NOUN
dpc-2053	197	14	of	of	ADP
dpc-2053	197	15	response	response	NOUN
dpc-2053	197	16	to	to	ADP
dpc-2053	197	17	omalizumab	omalizumab	NOUN
dpc-2053	197	18	and	and	CCONJ
dpc-2053	197	19	relapse	relapse	VERB
dpc-2053	197	20	in	in	ADP
dpc-2053	197	21	chronic	chronic	ADJ
dpc-2053	197	22	spontaneous	spontaneous	ADJ
dpc-2053	197	23	urticaria	urticaria	NOUN
dpc-2053	197	24	:	:	PUNCT
dpc-2053	197	25	a	a	DET
dpc-2053	197	26	study	study	NOUN
dpc-2053	197	27	of	of	ADP
dpc-2053	197	28	470	470	NUM
dpc-2053	197	29	patients	patient	NOUN
dpc-2053	197	30	.	.	PUNCT
dpc-2053	198	1	j	j	PROPN
dpc-2053	198	2	eur	eur	PROPN
dpc-2053	198	3	acad	acad	PROPN
dpc-2053	198	4	dermatol	dermatol	NOUN
dpc-2053	198	5	venereol	venereol	NOUN
dpc-2053	198	6	.	.	PUNCT
dpc-2053	199	1	2019;33(5):918	2019;33(5):918	NUM
dpc-2053	199	2	-	-	PUNCT
dpc-2053	199	3	924	924	PROPN
dpc-2053	199	4	.	.	PUNCT
dpc-2053	200	1	doi	doi	NOUN
dpc-2053	200	2	:	:	PUNCT
dpc-2053	200	3	10.1111	10.1111	NUM
dpc-2053	200	4	/	/	SYM
dpc-2053	200	5	jdv.15350	jdv.15350	PROPN
dpc-2053	200	6	.	.	PUNCT
dpc-2053	201	1	pmid	pmid	NOUN
dpc-2053	201	2	:	:	PUNCT
dpc-2053	201	3	30451325	30451325	NUM
dpc-2053	201	4	.	.	PUNCT